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INTRODUCTION 
 
Gastroesophageal reflux disease is multifactorial process and a common 
problem which accounts for a sizeable proportion in terms of health care costs 
to diagnose and treat the condition1. 
 
DEFINITION  
The reflux of acid, particularly after meals, is a physiologic process, the 
simple presence of gastroesophageal reflux (GER) or occasional symptoms of 
heartburn or acid regurgitation cannot be defined as a disease. 
GERD is the failure of normal antireflux barrier to protect against 
frequent and abnormal amounts of gastric contents moving retrograde 
effortlessly from the stomach into the esophagus. A  globally acceptable 
Montreal definition and classification of GERD  can be applied in clinical 
practice and in research2. This international group defined GERD as                
“a condition which develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications.” Troublesome symptoms are 
defined by the patient to affect their quality of life. Mild symptoms occurring    
2 or more days per week or moderate to severe symptoms occurring more than 
1 day per week are often considered troublesome by patients. Patients may be 
diagnosed based on typical symptoms alone or on tests demonstrating reflux of 
stomach contents (e.g. pH testing, impedance monitoring) or the injurious 
effects of the refluxate (endoscopy, histology, electron microscopy), in the 
presence of typical or atypical symptoms or complications. This new definition 
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also recognizes that the refluxate causing symptoms may be weakly acidic or 
gaseous. 
The group further divided the manifestations of GERD into esophageal 
and extraesophageal syndromes, with extraesophageal syndromes divided into 
established and proposed associations. In primary care, most patients are 
initially uninvestigated and present with symptomatic syndromes, either typical 
reflux complaints of heartburn and regurgitation or reflux-related chest pain. 
After investigation, usually endoscopy with histology, patients can be further 
classified as having the “syndromes with mucosal injury” to include reflux 
esophagitis, stricture, Barrett esophagus, or esophageal adenocarcinoma.       
The  definition thus allows symptoms to define the disease but permits further 
characterization if mucosal injury is found. This group also recognized 
laryngitis, cough, asthma, and dental erosions as possible extraesophageal 
syndromes of GERD. The statement was restrained in defining a causal 
relationship, however, because of the lack of high-level evidence, especially 
showing a beneficial effect of reflux treatments on the extraesophageal 
syndromes and the reality that these syndromes are usually multifactorial, with 
GERD as one of several potential aggravating cofactors. 
 
EPIDEMIOLOGY 
The  incidence of GERD,  defined  as at least weekly heartburn and/or 
acid regurgitation,  in the Western world generally ranges between 15% and 
25%, whereas in Asia the prevalence is reported to be less than 5%3,4. Time 
trends confirm a significant increase in the prevalence of reflux symptoms 
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averaging 5% annually in North America, 27% annually in Europe, and only 
1% in Asia possibly because of lower dietary fat, lower BMI and low acid 
output due to H.pylori infection among Asians4 although the scenario is 
changing on account of changing diet habits, increasing BMI and H.pylori 
eradication among Asians. The disease is a relapsing and remitting disorder, 
but in contrast to the data for period prevalence, there are few longitudinal 
studies that describe the incidence of heartburn in the population. Based on 
only two studies from the Western world, the incidence of GERD can be 
estimated at 5 per 1000 person-years or an adjusted yearly incidence of weekly 
heartburn of approximately 1.5% to 3%. 
Even less is known about the prevalence of reflux esophagitis.                
A population-based endoscopic study suggests that asymptomatic esophagitis is 
common. In a random sample of a Swedish adult population, reflux symptoms 
were reported by 40% and esophagitis was diagnosed in nearly 16%. One third 
of those who had esophagitis, however, had no symptoms of GERD5. Two 
other population-based studies found the prevalence of esophagitis to be nearly 
12% in Italy but only 7% in Japan4. 
 
RISK FACTORS 
Age: The effect of increasing age on the prevalence of GERD symptoms is 
unclear. European studies report a slight but significant association, but the 
relationship was not observed for heartburn with or without acid regurgitation6. 
A recent study suggested an association between advancing age and milder 
reflux symptoms but more severe esophagitis 7.  
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Gender: All studies report a similar prevalence of heartburn in men and 
women5. On the other hand, endoscopy database studies find male sex a 
significant risk factor for reflux esophagitis8. 
BMI: Cross-sectional studies and systematic reviews consistently find that 
obesity is associated with a statistically significant increase in the risk for 
reflux symptoms, erosive esophagitis, Barrett esophagus, and esophageal 
adenocarcinoma9,10,11.  In these studies, obesity (BMI >25) was associated with 
2.5- to 3.0-fold increase in these presentations of GERD.  
Helicobacter Pylori Infection:  an environmental factor that has declined as 
GERD, Barrett esophagus, and esophageal adenocarcinoma have increased in 
developed countries12. A systematic review of observational studies has 
confirmed that there is a negative association between H pylori and GERD, 
although this finding is most apparent in Asian countries13. The causative 
mechanism for this protective effect is the H pylori-induced gastritis, involving 
the antrum and corpus, which decreases the parietal cell mass, reduces acid 
secretion, and elevates gastric pH14. 
Genetics: There have been two studies15,16 assessing the prevalence of reflux 
symptoms in monozygotic versus dizygotic twins. Data from the Swedish Twin 
Registry15 suggested that 31% (95% CI, 23%–39%) of GERD is caused by 
additive genetic factors, whereas a United Kingdom Twin Registry study16 
reported that this value was 43% (32%–55%). Although one group defined a  
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locus on chromosome 13 associated with severe pediatric GERD17,  this has not 
been confirmed in adults. The genetic mechanisms are unknown but may be 
related to a smooth muscle disorder associated with hiatal hernia, low LES 
pressure, and impaired esophageal motility 
PATHOGENESIS: ROLE OF OBESITY 
GERD results from an imbalance between defensive factors protecting 
the esophagus (antireflux barriers,esophageal acid clearance,tissue resistance) 
and aggressive factors from the stomach (gastric acidity,volume and duodenal 
contents).  Parallel increase in prevalence of GERD and obesity in the West led 
to studying of obesity as a contributing factor95. Obesity may alter the anatomy 
of the antireflux barrier in the following ways: 
 Pressure and integrity of the diaphragmatic crura which prevents  
` reflux during sneezing,coughing,bending is compromised 
 Lax phrenoesophageal ligaments  
 Change in the acute angle of His 
 Hiatus hernia associated with abdominal obesity alters the intra  
abdominal location of lower esophageal sphincter,causes lower  
basal LES pressure96, eliminates the increase in LES pressure  
during straining, increases the transient LES relaxations during  
gastric distention,97,98  impairs esophageal acid clearance99 and  
alters esophagogastric junction compliance100  
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CLINICAL PRESENTATIONS   
 
Heartburn and acid regurgitation are the classic symptoms of GERD. 
Heartburn describes a burning feeling, rising from the stomach or lower chest 
and radiating toward the neck, throat, and occasionally, the back18. It occurs 
postprandially, particularly after large meals or after eating spicy foods, citrus 
products, fats, chocolates, or drinking alcohol. The supine position or bending 
over may exacerbate heartburn. Night time heartburn may cause sleeping 
difficulties and impair next-day function19. The frequency and severity of 
heartburn does not predict the degree of esophageal damage7. The effortless 
regurgitation of acidic fluid, especially after meals and worsened by stooping 
or the supine position is suggestive of GERD. Among patients who have daily 
regurgitation  LES pressure is usually low, many have associated gastroparesis, 
and esophagitis is common, making this symptom more difficult to treat than 
classic heartburn. Symptoms such as dysphagia, odynophagia, globus 
sensation, burping, water brash, and cough are other possible presentations of 
GERD, but their diagnostic yield is uncertain. Odynophagia may be seen with 
severe reflux esophagitis, but usually suggests an infection or pill-related 
esophagitis. Water brash is the sudden appearance in the mouth of a salty fluid. 
It is not regurgitated fluid, but rather secretions from the salivary glands in 
response to acid reflux20. 
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The clinical accuracy of heartburn or regurgitation in diagnosing GERD 
is difficult to define.  A recent systematic review21 identified seven studies that 
assessed the accuracy of these reflux symptoms in diagnosing GERD in more 
than 5000 patients. Endoscopy with the presence of esophagitis has excellent 
specificity; thus, it was used as the gold standard to assess the sensitivity of 
heartburn and regurgitation. Unfortunately the sensitivity of these classic reflux 
symptoms was poor, with a range of 30% to 76% and a pooled sensitivity of 
55% (95% CI, 45% – 68%). Many patients who have atypical upper 
gastrointestinal (GI) symptoms thus may have GERD. 
Some patients who have GERD are asymptomatic. This is particularly 
true in elderly patients, perhaps because of reduced gastric acidity from chronic 
H pylori infection or decreased pain perception. Many elderly patients present 
first with complications of GERD because of long-standing disease with 
minimal complaints. For example, up to one third of patients who have Barrett 
esophagus are insensitive to acid at the time of presentation22. 
DIAGNOSTIC TESTS  
A large number of tests are available for evaluating patients who have 
suspected GERD. Many times these tests are unnecessary, because the presence 
of frequent heartburn and acid regurgitation are sufficiently accurate to identify 
the disease and begin medical treatment. This is not always the case, however, 
and clinicians must decide which tests to choose so as to make the diagnosis in 
a reliable, timely, and cost-effective manner, depending on the information 
desired (Table 1)23. 
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Diagnostic tests for gastroesophageal reflux disease 
 
Tests for reflux  
•    Intraesophageal pH monitoring 
•    Ambulatory bilirubin monitoring (bile reflux) 
•    Ambulatory impedance and pH monitoring (non-acid reflux) 
•    Barium esophagram 
 
Tests to assess esophageal mucosal damage  
•    Endoscopy 
•    Esophageal mucosal biopsy 
•    Barium esophagram 
 
Tests to assess symptoms  
•    Empirical trial of PPIs 
•    Intraesophageal pH monitoring with symptom analysis 
 
Tests to assess esophageal function  
•    Esophageal manometry 
•    Esophageal impedance 
•    Barium esophagram with fluoroscopy 
 
Upper Endoscopy  
The identification of esophagitis at the time of endoscopy is highly 
specific (90%–95%) for GERD24 but has a sensitivity of only approximately 
50%. Multiple classification systems for esophagitis have been proposed, some 
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are confusing, and none have worldwide acceptance25. The most thoroughly 
evaluated esophagitis classification is the Los Angeles (LA) system, which is 
gaining acceptance in the United States and Europe (Fig. 3)26. In referral 
centers, approximately 50% of patients have esophagitis, but in primary care 
and the general population, the rate of esophagitis is more in the range of 10% 
to 30%4.  Most patients who have esophagitis have mild LA grade A-B disease 
and only 10% have the more severe LA grade C-D esophagitis27.  Endoscopy 
can also evaluate complications of GERD, such as peptic strictures and Barrett 
esophagus and is recommended if patients have alarm symptoms, such as 
progressive dysphagia, weight loss, or iron deficiency anemia28. In routine 
clinical practice, endoscopy is reserved for evaluating patients who have alarm 
symptoms, for suspected GERD complications, and for surveillance for Barrett 
esophagus in patients who have chronic reflux complaints29. 
 
Biopsy: Over the years esophageal biopsies have had a varying role in the 
evaluation of GERD. The presence of eosinophils (<15 per high powered field) 
and markers of increased epithelial turnover (basal cell hyperplasia and 
prolongation of rete peg) have reasonable sensitivity but poor specificity, 
whereas neutrophils in the esophageal mucosa are specific but not sensitive30. 
Electron microscopy of esophageal biopsies suggests that dilated intercellular 
spaces could be an early marker of mucosal injury, whereas the endoscopy still 
seems normal (Fig. 4)31,32. Several studies consistently find the intercellular 
spaces at least two to three times greater in patients who have erosive and 
nonerosive GERD compared with healthy control subjects32.  Aggressive acid 
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suppression therapy seems to normalize the width of the intercellular spaces32. 
Unfortunately these spaces are more difficult to define by light microscopy.     
In clinical practice, biopsies are usually not taken in patients who have classic 
reflux esophagitis unless necessary to exclude neoplasm, infection, pill injury, 
bullous skin disease, or eosinophilic esophagitis (>20 eosinophils per HPF). 
The current primary indication for esophageal biopsies is to determine the 
presence of Barrett epithelium29.  When this diagnosis is suspected, biopsies 
are mandatory and best done when esophagitis is healed. 
  
Esophageal pH Monitoring   
Ambulatory intraesophageal pH monitoring is the standard for 
establishing pathologic reflux23. Traditionally the pH probe is passed nasally, 
positioned 5 cm above the manometrically determined LES, and connected to a 
battery-powered data logger capable of collecting pH values every 4 to 6 
seconds for 24 hours. Patients record meals, sleeping, and when symptoms are 
experienced. Acid reflux episodes are defined as a pH drop of less than 4. The 
total percent of time the pH is less than 4 is the most reproducible measure of 
GERD, with the reported upper limits of normal ranging from 4% to 5.5%33. 
The sensitivity of 24-hour pH monitoring in patients who have esophagitis 
approaches 90% with a specificity of 85% to 100%. In patients who have 
normal endoscopy in which pH testing may be most needed, the sensitivity is 
only 60% and the specificity from 85% to 90%34.  Clinical indications for 
ambulatory pH monitoring include (1) before fundoplication to insure the 
presence of pathologic reflux in patients who have a normal endoscopy,         
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(2) after antireflux surgery if heartburn symptoms persist, (3) patients who have 
reflux symptoms and a normal endoscopy not responding to PPI treatment, and 
(4) patients who have suspected extraesophageal symptoms of GERD34. 
 
 Two new advances are improving the role of pH testing in evaluating 
GERD. The first is a wireless device (Bravo pH probe, Medtronics, 
Minneapolis, MN) the size of a vitamin pill attached, usually by endoscopy, 6 
cm above the Z-line (Fig. 5)35. This decreases patient discomfort, allows for 
longer (48 hours or more) monitoring, and may increase test sensitivity by 
allowing patients to more comfortably carry out their usual activities36. The 
capsule detaches and passes spontaneously within 2 weeks. Rare patients may 
note severe pain after attachment, which resolves spontaneously with 
endoscopic removal. Two significant complications have occurred with this 
device—one report of esophageal bleeding requiring transfusion and one 
esophageal perforation37. 
            The second technologic advancement combines multichannel 
intraluminal impedance monitoring with pH sensors to detect acid, weak acid, 
and non-acid reflux using a transnasal catheter over 24 hours38. The number of 
respective reflux episodes, rather than percentage of exposure time, is the 
critical measurement, with normal values established from United States and 
European studies38. The results of several studies suggest that impedance-pH 
monitoring is useful in the evaluation of patients who have PPI-resistant typical 
reflux symptoms, especially regurgitation complaints, and chronic unexplained 
cough39,40,41. 
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Barium Esophagram  
The barium esophagram is inexpensive and less invasive than 
endoscopy. It is most useful in demonstrating strictures, rings, hiatus hernias, 
and major abnormalities in peristalsis. The barium esophagram's ability to 
detect esophagitis varies, with sensitivities of 79% to 100% for moderate to 
severe esophagitis, whereas mild esophagitis is usually missed23. It is also not 
reliable for detecting Barrett esophagus. 
 
Esophageal Manometry  
Esophageal manometry allows assessment of LES pressure and 
relaxation and peristaltic activity, including contraction amplitude, duration, 
and velocity. It is generally not indicated in the evaluation of patients who have 
uncomplicated GERD, however, because most have normal resting LES 
pressure42.  Esophageal manometry to document adequate esophageal 
peristalsis is traditionally recommended before antireflux surgery. If the study 
identifies ineffective peristalsis (low amplitude or frequent failed peristalsis), 
then a complete fundoplication may be contraindicated. This assumption has 
recently been challenged, however, by several studies finding that reflux 
control was better and dysphagia no more common in patients who had weak 
peristalsis after a complete as opposed to partial fundoplication43. An 
improvement of traditional manometry, combining it with impedance testing, is 
helping to clarify this controversy. Using this technology, a recent study found 
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that less than 50% of patients who had ineffective peristalsis had a significant 
delay in esophageal bolus transit measured by impedance44. 
Proton Pump Inhibitor Test  
An empiric trial of acid suppression is the simplest method for 
diagnosing GERD and assessing its relationship to symptoms. With the advent 
of PPIs, this test has become the first diagnostic study used in patients who 
have classic or atypical reflux symptoms without alarming complaints. 
Symptoms usually respond to a PPI test in 1 to 2 weeks. If symptoms disappear 
with therapy and then return when medication is discontinued, GERD is 
established. A systematic review45 identified 15 studies that assessed the 
accuracy of normal or high dose PPIs for 1 to 4 weeks in the diagnosis of 
GERD. The pooled sensitivity was good at 78% (95% CI, 66%–86%), but the 
specificity was poor at 54% (95% CI, 44%–65%) when 24-hour ambulatory pH 
was used as a gold standard. Nevertheless an empiric PPI trial for diagnosing.  
GERD offers many advantages: the test is office-based, easily done, 
inexpensive (especially with over-the-counter PPIs), available to all physicians, 
and may avoid needless procedures. For example, one study showed a savings 
of greater than $570 per average patient because of a 59% reduction in the 
number of diagnostic tests (upper endoscopy, pH tests)46. Disadvantages are 
few, but include a placebo response and uncertain symptomatic endpoint if 
symptoms do not totally resolve with extended treatment. 
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Complications 
There are few data on the long-term outcome of patients who have 
varying severities of GERD. Severity and duration of symptoms seem to have a 
poor correlation with the presence or severity of esophagitis7. Furthermore, 
there is some controversy whether GERD exists as a spectrum of disease 
severity or as a categoric disease in three distinct groups: nonerosive and 
erosive reflux disease and Barrett esophagus24,47. The recent European 
ProGERD study involving nearly 4000 patients sheds some light on the 
progression or regression of GERD over 2 years47. After endoscopy to assess 
the presence or absence of esophagitis, all patients were treated with 4 to 8 
weeks of esomeprazole then returned to their primary care physician. Two 
years later all patients underwent a second endoscopy with biopsies. As shown 
in Fig. 6, after 2 years 25% of patients who had nonerosive GERD progressed 
to LA grade A-B esophagitis but severe LA grade C-D esophagitis was rare 
(<1%). Likewise, only 1.6% of LA grade A-B patients progressed to severe 
disease, whereas most (61%) regressed to nonerosive disease. Even the severe 
LA grade C-D patients had a good prognosis, with 42% regressing to milder 
esophagitis and 50% regressing to a nonerosive state. Patients who had LA 
grade C-D esophagitis were at a greater risk 2 years later for developing Barrett 
esophagus: 5.8% compared with 1.4% for LA grade A-B and 0.5% for 
nonerosive disease. These data suggest GERD more likely is a spectrum of 
disease that tends to regress in severity after it comes to medical attention, 
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regardless of treatment. The progression of Barrett esophagus may be an 
artifact of better detection after esophagitis has healed48. 
Peptic Esophageal Strictures  
Esophageal strictures have a prevalence of approximately 0.1% and are 
associated with white race, male gender, and increasing age49. Patients usually 
present with dysphagia for solids, but unlike malignant strictures, weight loss is 
uncommon because their appetite is good. As dysphagia progresses, heartburn 
often decreases, reflecting the stricture acting as a barrier to further reflux. 
Peptic strictures are smooth walled, tapered, circumferential narrowing in the 
lower esophagus that are usually less than 1 cm long. A mid to upper 
esophageal stricture should raise concern about Barrett esophagus or 
malignancy. Although once controversial, today a Schatzki ring is considered a 
forme fruste of an early peptic stricture50.  All stricture patients should undergo 
endoscopy, at least initially, to confirm the benign nature of the disease and, if 
necessary, to take biopsies to exclude cancer and Barrett esophagus. 
Symptomatic patients can be dilated by various bougies51. Dysphagia relief 
generally occurs when the lumen is greater than 15 mm and associated 
esophagitis has healed52. 
Barrett Esophagus  
Barrett esophagus is the consequence of severe GERD in which the 
squamous epithelium of the distal esophagus is replaced by specialized 
columnar mucosa containing goblet cells (intestinal metaplasia). The disease is 
more common in white men, rare before age 50 years, and present in 1% to 2% 
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of patients referred for endoscopy over this age threshold8. Bile reflux and 
obesity have been associated with an increased risk for Barrett esophagus9,53. 
The diagnosis can be suspected at endoscopy and its circumferential 
involvement and maximum proximal extension described using the new Prague 
classification54.  Histology is required, however, to confirm the diagnosis and 
to define the potentially premalignant intestinal metaplasia. Detection of 
Barrett esophagus is highest after suspected patients have been on PPIs for 8 to 
12 weeks48. In the era of PPIs, Barrett esophagus is easy to treat and only of 
major interest because of an increased risk for developing esophageal 
adenocarcinoma, estimated at between 0.5% and 1% each year55. Increased 
duration, frequency, and severity of reflux symptoms have been shown to be 
risk factors for this cancer56,57,58. 
Extraesophageal Manifestations  
Gastroesophageal reflux may be the cause of a wide spectrum of 
conditions, including non-cardiac chest pain, asthma, posterior laryngitis, 
chronic cough, recurrent pneumonitis, and even dental erosion59.  GERD-
related chest pain may mimic angina pectoris, even to the point of being 
induced by exercise. Most of these patients also have heartburn symptoms60. 
The mechanism of the pain is poorly understood, likely because of the volume 
and duration of acid reflux, secondary esophageal spasm, or prolonged 
contractions of the longitudinal muscle61. The causal link between GERD and 
pulmonary and ear, nose, and throat complaints is much more circumspect59. 
Although the possible mechanisms from animal studies are plausible            
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(i.e., microaspiration and vagal reflex), most suspected patients are heartburn-
free and do not have esophagitis, hiatus hernia, or low LES pressure. 
Unfortunately pH testing (distal or proximal), although frequently abnormal in 
these patients, does not predict their response to medical or surgical therapies. 
Medical Treatment  
Lifestyle and Over-the-Counter Medications:  
Numerous dietary and lifestyle modifications are advocated for the 
treatment of GERD. They are frequently first-line therapy for patients who 
have mild disease and often adjunct therapy even for patients on PPIs. In a 
recent evidence-based review, studies of smoking, alcohol, chocolate, fatty 
foods, and citrus products showed physiologic evidence that their intake can 
adversely affect symptoms or esophageal pH. There was little evidence, 
however, that cessation of these products predictably improved GERD 
symptoms. Only elevation of the head of the bed, left lateral decubitus 
positioning, and weight loss was associated with GERD improvement in case-
controlled studies62. 
Over-the-counter (OTC) antacids and H2RAs are useful in treating mild 
and infrequent heartburn symptoms, especially when symptoms are brought on 
by lifestyle indiscretions. In one recent meta-analysis63, the relative benefit 
increase compared with the overall placebo response was up to 41% with 
H2RAs, 60% with alginates, and 11% with antacids. Antacids rapidly relieve 
heartburn symptoms, the major reason these drugs are so popular for mild, 
intermittent symptoms. Although their onset of relief is not as rapid as antacids, 
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OTC H2RAs have a longer duration of action, up to 6 to 10 hours. From a 
practical standpoint, they are most useful when taken before a potentially 
refluxogenic activity, such as a heavy meal, eating late at night, or exercise.  
Proton Pump Inhibitors  
PPIs revolutionized the treatment of GERD and currently are the 
mainstay of acute and maintenance treatment regimens. This class of drugs 
markedly diminishes gastric acid secretion over a 24-hour period by inhibiting 
the final common pathway of acid secretion, the H+K+ ATPase pump. Their 
superior efficacy compared with H2RAs is based on their ability to maintain an 
intragastric pH of less than 4 between 15 and 21 hours, compared with 
approximately 8 hours daily with H2RAs. 
In a recent Cochrane review64, PPIs were more effective than placebo in 
healing esophagitis (RR = 0.23; 95% CI, 0.01–0.05) with a number to treat 
(NNT) of 2 (95% CI, 1.4–2.5). The review also identified 26 trials involving 
4064 patients that compared PPIs with H2RAs. PPIs were superior to H2RAs 
in healing esophagitis at 4 to 6 weeks (RR = 0.47; 95% CI, 0.41–0.53) with an 
NNT of 3 (95% CI, 2.8–3.6). Another Cochrane systematic review found that 
PPI therapy was superior to placebo and H2RAs in endoscopy-negative GERD 
and undiagnosed reflux symptoms in primary care, although the effect was not 
as marked as with esophagitis65. Cochrane reviews also have identified the 
superiority of PPIs over H2RAs in maintaining the remission of esophagitis 
over 6 to 12 months66. Among 10 randomized trials, the relapse rate for 
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sophagitis was 22% on PPIs compared with 58% on H2RAs, with an NNT of 
2.5 (95% CI, 2.0–3.4). 
Until recently the therapeutic efficacy between PPIs was similar. Recent 
large randomized controled trial (1000–2500 patients), however, have found 
the newest PPI, esomeprazole 40 mg, superior to omeprazole 20 mg and 
lansoprazole 30 mg in healing esophagitis67. The therapeutic advantage is 
minimal with mild LA grade A-B esophagitis (NNT 50 and 33, respectively) 
and greatest with severe LA grade C-D esophagitis (NNT 10 and 8, 
respectively). This superiority is related to higher systemic bioavailability and 
less inter-patient variability with esomeprazole. 
 
Treatment Of Complicated Gastroesophageal Reflux Disease And Its 
Extraesophageal Presentations  
 
The extensive use of PPIs has markedly affected treatment of peptic 
strictures and esophageal rings. Several studies note an approximate 33% 
decline in the incidence of recurrent strictures. The timeline for this decrease 
parallels the marked increase in PPI use since 1995 (Fig. 7)68. Another study 
convincingly shows that in patients who have symptomatic Schatzki rings, 
maintenance PPI therapy after bougienage markedly decreases future relapses 
of the rings69. In a randomized study, 30 patients who had symptomatic rings 
without esophagitis were dilated and randomized to placebo or omeprazole 20 
mg per day. In the treated group, one patient relapsed after 13 months, whereas 
seven patients relapsed on placebo after a mean of 20 months. 
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The efficacy of PPI treatment in the extraesophageal presentations of 
GERD is more variable. There are two systemic reviews70,71, both suggesting 
that patients who have non-cardiac chest pain respond to PPIs better than to 
placebo. These reports identified eight RCTs that assessed 321 patients who 
had a pooled relative risk for continued chest pain after PPI therapy, compared 
with placebo of 0.54 (95% CI, 0.41–0.71), with an NNT of 3 (95% CI, 2–4). 
Systemic reviews, however, do not support the efficacy of aggressive acid 
suppression, particularly with PPIs in other extraesophageal disorders, such as 
chronic cough72, asthma73, or ear, nose, and throat disorders74. 
Sleep disturbances may occur in up to 75% of patients who have GERD, 
impairing quality of life. In a large multicenter study, patients who had GERD-
associated sleep disturbances and nighttime heartburn were randomized to two 
doses of esomeprazole (40 mg and 20 mg) or placebo for 4 weeks75. GERD-
related sleep disturbances resolved in significantly more patients on 
esomeprazole 40 mg (73.7%) or 20 mg (73.2%) than those who received 
placebo (41.2%). These changes were associated with improved sleep quality 
and daytime productivity. 
Refractory Gastroesophageal Reflux Disease  
Traditionally patients who have reflux symptoms no longer undergo 
initial endoscopy, but rather are given a 4- to 8-week trial of a PPI. Failure to 
improve occurs in 25% to 42% of patients, thus placing them in a more 
difficult to manage group. At this point the physician should insure patient 
compliance and review timing of the PPI dose (1/2 to 1 hour before meals). 
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One recent study found that nearly 70% of primary physicians and 20% of 
gastroenterologists gave the PPI at bedtime or did not believe the relationship 
to meals was important76. Switching to a second generation PPI (i.e., 
pantoprazole, esomeprazole) may be a reasonable alternative. This was recently 
confirmed in a multicenter study of patients who had persistent heartburn 
symptoms while receiving lansoprazole 30 mg once daily77. Switching to a 
single dose of esomeprazole (40 mg) was as effective as twice daily 
lansoprazole in relieving heartburn complaints over 8 weeks of therapy. Most 
physicians, however, increase the current PPI to twice daily dosing (before 
breakfast and dinner), with up to 25% of patients responding78. 
Those patients doing no better fall into the “refractory GERD” 
category79. The critical diagnostic test is upper GI endoscopy, which identifies 
patients who have esophagitis or no esophagitis. The largest percentage of 
these patients have refractory symptoms with no esophagitis. These patients 
may require 24-hour pH testing on PPI therapy, impedance testing, and 
consideration of other diagnoses, such as achalasia, gastroparesis, and 
functional heartburn.  
Safety Concerns  
Initial concerns about PPIs causing gastric malignancies in rats have not 
been substantiated in other animal models or long-term patient studies. Fundic 
gland polyps are the most common gastric polyp found at endoscopy. Their 
association with chronic PPI use has been a topic of debate since these drugs 
were first described. A recent study evaluated 599 patients of whom 322 used 
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PPIs and 107 had fundic gland polyps80.  Long-term PPI use was associated 
with up to a fourfold increase in the risk for fundic gland polyps. Low-grade 
dysplasia was found in one fundic gland polyp. Etiologically these polyps seem 
to arise because of parietal cell hyperplasia and parietal cell protrusions 
resulting from acid suppression. 
Recent studies confirm that chronic acid suppression may be associated 
with an increased risk for community-acquired pneumonias and enteric 
infections. In a large Scandinavian population-based study81, the adjusted 
relative risk for pneumonia among current PPI users compared with those who 
stopped using PPIs was 1.89 (95% CI, 1.36–2.62). Current users of H2RAs had 
a 1.63-fold increased risk for pneumonia (95% CI, 1.07–2.48) compared with 
those who stopped. A significant positive dose–response relationship was 
observed in the PPI users. Likewise a recent systematic review found an 
increased risk for enteric infections with acid suppression82. The correlation 
was stronger with Salmonella, Campylobacter, and other enteric infections 
compared with Clostridium difficile, and greater with PPI compared with 
H2RA therapy. 
PPIs also may alter calcium metabolism through induction of 
hypochlorhydria interfering in insoluble calcium absorption or through reduced 
bone resorption through inhibition of osteoclastic vacuolar proton pumps. In a 
recent nested case-control study83.  the risk for hip fractures was significantly 
increased among patients prescribed more than 1 year of PPI therapy (OR, 
1.44; CI, 1.30–1.59) and among those on long-term, high-dose PPIs             
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(OR, 2.65; 95% CI, 1.80–3.90; P<.001). The strength of the association 
increased with increasing duration of PPI therapy.  For elderly patients 
requiring long-term PPIs, it may be prudent to re-emphasize increased calcium 
intake, preferably from a dairy source, and co-ingestion of a meal when taking 
insoluble calcium supplements. 
New Drug Treatments  
New drug treatments have primarily targeted transient LES relaxation, 
the common motility abnormality in all forms of GERD. Several agents, 
including cholecystokinin A agonists, anticholinergic drugs, nitric oxide 
synthase inhibitors, morphine, cannaboid, and gamma-aminobutyric acid B 
(GABA) agonists have been shown to reduce transient LES relaxation and 
episodes of acid reflux84.  The only agent available for oral therapy is baclofen, 
a GABA agonist. Several studies show that 10 to 20 mg of baclofen three to 
four times daily for up to 4 weeks reduces 24-hour esophageal acid and 
bilirubin reflux85,86.  Baclofen needs to be titrated upward slowly, beginning at 
5 mg daily and increased over 10 days to 40 to 60 mg per day. Side effects are 
common and include drowsiness, nausea, and the lowering of the threshold for 
seizures. New compounds with more specific and better targeted action need to 
be developed. Another approach has been to develop newer rapid-acting PPIs, 
such as potassium-competitive acid blockers (P-CAB). Unlike the traditional 
PPIs that bind irreversibly to the proton pump, this new class of compounds 
blocks acid secretion by way of potassium-competitive inhibition of the H+K+ 
ATPase. This results in rapid onset with almost complete acid blockade 
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achieved within 30 minutes of administration84.  Unfortunately recent phase III 
studies found the P-CABs no more effective than esomeprazole in the rapid 
relief of heartburn symptoms. 
Endoscopic Treatment  
Various endoscopic techniques for the treatment of GERD have been 
developed as alternatives to antisecretory therapy or antireflux surgery87.  
These techniques include the delivery of radiofrequency energy to the 
gastroesophageal junction, injection of bulking agents , or implantation of a 
bioprosthesis  into the LES, and suture plication of the proximal gastric folds 
(Endoscopic Plication System). Studies to date have primarily enrolled PPI-
dependent patients who do not have severe esophagitis or large hiatus hernia. 
Each of these techniques decreases reflux symptoms, improves quality of life, 
and decreases the need for antisecretory medications. Physiologic studies, 
however, are much less impressive, with LES pressure rarely increasing, pH 
normalizing in only 30% of patients, and even mild esophagitis infrequently 
healing. Sham studies show a decrease in heartburn symptoms and improved 
quality of life after the active therapy compared with the sham group after 3 to 
6 months87. Only the Plication study showed a significant decrease in pH 
values, by only 18%, whereas no change in pH or LES parameters was 
observed in studies using the other techniques88. 
Most studies of endoscopic therapy have only limited follow-up 
information on a small number of patients. The durability of these techniques 
beyond 1 to 2 years remains unclear and seems to gradually decrease over time. 
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The cost-effectiveness of these techniques is difficult to define. Most 
important, safety issues have haunted these procedures, especially when used in 
the broader community of gastroenterologists. Chest pain, bleeding, esophageal 
perforations, mediastinitis, and at least 8 deaths to date have been attributed to 
these endoscopic techniques. Serious adverse events, including deaths, led to 
the American Gastroenterological Association Institute medical position 
statement recommending that “current data suggest that there are no definite 
indications for endoscopic therapy for GERD at this time”87. 
Surgical Management  
Only surgical fundoplication can correct the physiologic factors 
contributing to GERD and prevent the need for long-term medication. 
Successful antireflux surgery involves (1) reducing the hiatal hernia back into 
the abdomen, (2) closing the opening in the diaphragmatic hiatus, (3) 
lengthening the intra-abdominal portion of the LES, and (4) strengthening the 
repair with a fundoplication. The most popular fundoplication is the 360° 
Nissen fundoplication. The partial posterior Toupet fundoplication is primarily 
used in patients who have aperistalsis or ineffective esophageal peristalsis. The 
latter is associated with less bloating and flatus, but not necessarily dysphagia 
when compared with a total fundoplication89. Most authorities in the United 
States believe the Nissen fundoplication is more durable. 
Antireflux surgery has undergone a resurgence since the advent of the 
laparoscopic operation90. A systematic review identified six randomized 
controlled trials involving 449 patients that compared open and laparoscopic 
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fundoplication91. There was no significant difference in recurrence rates 
between the procedures, and laparoscopic fundoplication was associated with 
lower operative morbidity (NNT to prevent complication = 8; 95% CI, 3–16) 
and shorter hospital stay. 
Indications for surgical fundoplication in the era of inexpensive PPIs 
and proven long-term safety of these drugs89 are:  
1. Patients who have typical or atypical GER symptoms who respond to 
PPIs but who want surgery because of  
•    A desire for a permanent cure 
•    Patient preference 
•    An intolerance to PPIs 
2.  Failed medical therapy as a result of persistent volume regurgitation. 
Here heartburn symptoms are controlled, but regurgitation is a 
persistent problem. 
3.    Recurrent peptic strictures in younger patients 
4. Respiratory complications related to regurgitation and recurrent 
aspiration 
In patients who have Barrett esophagus, there is no convincing evidence 
that fundoplication reduces the long-term risk for esophageal 
adenocarcinoma92. 
Comparison studies of older medical treatments (antacids, H2RAs) 
consistently find surgical fundoplication better at healing esophagitis and 
relieving symptoms. There are few studies comparing fundoplication with 
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long-term PPI therapy, but one study93 suggested that both were equally 
effective in controlling symptoms over 5 years, provided patients in the 
medical treatment group were allowed to increase the dose of the drug to twice 
daily if necessary. 
Complications can occur after antireflux surgery, and many patients 
over time continue to require antireflux medications. In a database analysis, 
postoperative dysphagia was recorded in 19.4%, dilation was performed in 
6.4%, and a repeat antireflux surgery was needed in 2.3% of patients. The 
surgical mortality rate was 0.8%. Approximately 50% of patients received 
multiple prescriptions for antireflux medications at a median of 5 years of 
follow-up evaluation after their surgery. 
Tertiary specialized centers are seeing an increased rate of 
fundoplication failures94.  The most common reasons for failure are herniation 
of the intact fundoplication into the chest, slipped fundoplication with a 
recurrent hiatal hernia, probably caused by a short esophagus, paraesophageal 
hernia through an intact fundoplication, too tight a fundoplication, and 
malpositioned fundoplication, usually on the cardia of the stomach. Total 
breakdown of the fundoplication is now rare. Revisional antireflux surgery 
needs to be performed by experienced surgeons, can be done laparoscopically 
but many prefer an open approach, and has increased morbidity and mortality 
compared with the initial operation. 
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AIMS OF THE STUDY 
 
 
 
• To evaluate the association between Body Mass Index and 
      Gastroesophageal Reflux Disease. 
 
 
• To determine the correlation between Obesity and GERD in women. 
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REVIEW OF LITERATURE 
 
OBESITY AND GERD  
Obesity is increasing due to change in lifestyle and food habits among 
Indians. A recent survey of  urban Asian Indians in Chennai (CURES) has 
estimated the prevalence of obesity as 45.9% using the cutoff value of BMI 
>23 as per the recent definition among a representative population of 2350 
subjects106. 
WHO guidelines for Asians defines BMI >23 as overweight and >25 as 
obese101.  However recommended action points for BMI in Asians have defined 
BMI >23 as overweight and >27.5 as obesity, with the cutoff for morbid 
obesity being >37.5102. 
A study which studied cutoff for BMI in Asians based on mortality risk 
has defined >23 as overweight and >25 as obese103. 
There are studies which advocate abdominal obesity rather than whole 
body measurement such as BMI as a marker of obesity since Indians are lean 
but tend to have increased abdominal fat 
INTERHEART study has proposed waist hip ratio as a better marker of 
obesity than BMI104. 
There are other studies in favour of waist circumference as a better 
measure of obesity especially due to convenience of measuring it105 
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Studies indicate that gastro-esophageal reflux disease (GERD) is 
associated with obesity. 
Effect of obesity on the pathogenesis of hiatus hernia which contributed 
to GERD was the focus of Wiad Lek et al in 1974107. 
Lower esophageal sphincter pressure (LESP) and esophageal function 
was studied in obese patients in 1980108. 
Effect of obesity on esophageal transit was published in 1985110.  
Gastroesophageal reflux and obesity association109 and antireflux procedures 
such as the Angelchik antireflux prosthesis were studied in 1985111. 
Observation of the association between obesity and reflux disease, yielded 
conflicting conclusions among different studies; hence, the benefit of weight 
loss was also controversial. In a  large, Swedish population interview-based 
study, Lagergren et al112 concluded that the presence of gastroesophageal reflux 
symptoms occurred independently of BMI. However, this group (with the 
addition of Lindgren)56 had previously linked the presence of gastroesophageal 
reflux as a risk factor for esophageal adenocarcinoma, and Lagergren et al113 
have shown that this complication of GERD is, in fact, strongly associated with 
BMI. In a similar population-based study, using a questionnaire among the 
residents of Olmstead County, Minnesota, BMI was independently associated 
with GERD114.  Although earlier studies of the massively obese115,116 and 
investigations of the effect of weight loss therapy in symptomatic 
improvement117,118 were contradictory in their conclusions, further studies  are 
in favour of the association. 
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Body mass index was strongly positively related to the frequency of 
symptoms of gastro-oesophageal reflux, occurring at least once a week in 
overweight participants compared with those of normal weight and obese 
people are almost three times as likely to experience these symptoms as those 
of normal weight according to the Bristol Helicobacter Project in UK which 
examined the relationship between body mass and GER symptoms119. 
Lifestyle factors, in particular overweight, obesity and smoking, were 
associated with increased reflux symptoms in a representative sample of the 
general adult population in a German survey120. 
A large study which compared ethnic groups found that obesity may 
disproportionately increase GERD-type symptoms in the white population and 
in male subjects rather than blacks and Asians121. 
The report of the Asia-Pacific consensus on the management of 
gastroesophageal reflux disease summarizes the conclusions and 
recommendations of a panel of gastroenterologists practising in the Asia-
Pacific region. The group recognized that although gastroesophageal reflux 
disease (GERD) is less common and milder in endoscopic severity in Asia than 
in the West, there is nevertheless data to suggest an increasing frequency of the 
disease122. 
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An update of the Asia-Pacific consensus in 2008  notes that GERD is 
increasing in frequency in Asia. Risk factors include older age, male sex, race, 
family history, higher socioeconomic status, increased body mass index, and 
smoking123. 
Non-erosive reflux disease (NERD) appears to be the most common 
form of GERD among Asian patients with differing predisposition to GERD 
among different ethnic groups124. 
The prevalence of erosive esophagitis and Barrett's esophagus in a 
multiethnic Malaysian population was studied, as well as the relationship of 
various factors associated with reflux disease. There was a preponderance of 
Indians with esophagitis; Indians had the highest prevalence of Barrett's 
esophagus125. 
Indian race and BMI were among the risk factors for GERD in an 
endoscopy based study in a multiracial Asian population126. 
Abdominal obesity was the significant risk factor for erosive esophagitis 
in a Korean  endoscopy based study127. 
Another Japanese study showed similar conclusions that GERD and 
Hiatus hernia were related to obesity128. 
Asians tend to have a milder spectrum of the disease. Most Asian 
patients have non-erosive GORD; erosive oesophagitis is less commonly seen 
than in the Western population. Complicated GORD, such as oesophageal 
stricture and Barrett's oesophagus, is seldom encountered129. 
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The ProGERD study found that higher BMI was associated with more 
frequent and more severe heartburn, regurgitation and esophagitis. Obese 
women, not men had esophagitis compared to women of normal weight130. 
The link between body mass and reflux is much stronger in women than 
in men, at least in the few studies that did sex-specific analyses. There is a 
significant association between body mass and symptoms of gastroesophageal 
reflux. The association is stronger among women, especially premenopausally, 
and use of hormone therapy strengthens the association, suggesting that 
estrogens may play an important role in the etiology of reflux disease131. 
A study which examined diet, lifestyle and gender found that females 
had significantly higher prevalence of GERD than males (66 vs. 48%). Obesity  
was significantly related to GERD101. 
Prevalence of overweightedness and obesity is increased in female but 
not in male patients with ascertained gastro-esophageal reflux disease in an 
Italian study which compared patients with general population132. 
Estrogen treatment alone, but not with progestin, may cause GER 
symptoms in postmenopausal women. Increasing weight and girth increases the 
risk of developing GER symptoms, whereas weight loss alleviates existing 
GER symptoms in post menopausal females on hormone replacement 
therapy133. 
Association between BMI and symptoms of gastroesophageal reflux 
disease in a large cohort of women and a dose–response relationship was 
observed for both frequent and infrequent symptoms, nocturnal symptoms, and 
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for all degrees of the severity and duration of symptoms that were studied. 
Moreover, weight gain was associated with an increased risk of symptoms of 
gastroesophageal reflux disease, and weight loss was associated with a 
decrease in risk134. 
Esophagitis was significantly more prevalent in obesity than in normal 
subjects and association between GER and obesity remained significant 
adjusting for medication use in an endoscopy based study135.   
Oesophageal transit in obese reflux patients is slower than in their leaner 
counterparts,136 BMI is associated with the development of a hiatal hernia137,138 
(an important factor in delaying the clearance of acid from the oesophagus) and 
there is evidence that increasing BMI increases intra-abdominal pressure,139,140 
although this may be counteracted by equivalent increases in lower 
oesophageal sphincter pressure. 
Exposure of the distal esophagus to pathologic levels of refluxed gastric 
juices causes the clinical phenomenon of gastroesophageal reflux disease 
(GERD) and its sequelae. Reflux is prevented by a mechanically competent 
lower esophageal sphincter (LES), which provides a barrier between the gastric 
and esophageal compartments, and a proper clearance activity of the 
esophageal body by appropriate LES relaxation and peristaltic contractions on 
swallowing141,142. 
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Despite the presence of a structurally normal LES and effective 
esophageal clearance, excessive gastroesophageal reflux and consequent 
esophageal damage may still occur. In these patients, other factors must 
therefore exist that override the standard barrier to reflux.  
GERD  may be caused by an external alteration in the anatomical and 
physiological characteristics of the LES or esophageal body. Excessive fat 
deposition could interfere directly with the LES esophageal body complex, 
preventing it from functioning effectively, or it could change the intra-
abdominal pressure dynamics and render the barrier incompetent. 
The presence of excess fat in and around the gastroesophageal junction 
could alter the anatomical structure and, hence, the geometry of the cardia, 
placing the sphincter at a mechanical disadvantage to counter gas distension 
forces attempting to pull it open. The acute angle of His, an important 
anatomical structure preventing gastric wall tension from pulling the LES 
apart143 may become blunted, thus enabling moderate levels of gastric 
distension to more readily induce transient sphincter opening. Similarly, the 
potentiation effect on sphincter competency derived from the diaphragmatic 
crural sling144 may be attenuated if this region is surrounded by cushions of 
fatty tissue. 
Obese individuals have a higher intra-abdominal resting pressure, and 
this relates to the sagittal abdominal diameter145. Excess fat deposition in and 
around abdominal viscera, in addition to elevating intra-abdominal pressure, 
may interfere with and delay gastric emptying146. This promotes fundic 
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distension, with corresponding sphincter unfolding and length shortening, 
reducing its ability to function as an effective barrier147. The restriction of free 
space within the peritoneal cavity is likely to result in reduced pressure 
compliance within the abdominal compartment. Fluctuations in the intra-
abdominal pressure, such as occurs with positional or postural change, 
coughing, or straining, are therefore exaggerated, with sudden sharp rises in 
gastric pressure overcoming LES resistance. 
Retrospective analysis of body mass index in patients with normal 
esophageal manometric findings but with symptomatic and objectively 
confirmed gastroesophageal reflux found a strong correlation between body 
mass index and severity of gastroesophageal reflux. Patients who were 
overweight had significantly higher distal esophageal acid exposure148. 
A study to analyze the relationship between obesity and the morphology 
of the esophagogastric junction (EGJ) pressure segment using high-resolution 
manometry: The association between anthropometric variables and pressure 
values were examined there was a significant correlation of body mass index 
(BMI) and waist circumference (WC) with intragastric pressure  and 
gastroesophageal pressure gradient (GEPG)  Multivariate analysis adjusting for 
age, gender, and patient type did not alter the direction or magnitude of this 
relationship. In addition, obesity was associated with separation of the EGJ 
pressure components.Obese subjects are more likely to have EGJ disruption 
(leading to hiatal hernia) and an augmented GEPG providing a perfect scenario 
for reflux to occur149 
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During the postprandial period, both obese and overweight patients had 
substantial increase in 2-hour rate of transient lower esophageal sphincter 
relaxation (TLOSR) with acid reflux  and gastroesophageal pressure gradient 
(GOPG). BMI  and waist circumference  significantly correlated with TLOSR. 
Obesity is associated with increased TLOSR and acid reflux during the 
postprandial period. Abnormal postprandial LOS function may be an early 
event in the pathogenesis of obesity-related GERD150. 
Obesity may promote the development of GERD through the 
mechanical stresses imposed on the antireflux barrier, specifically increased 
pressure gradients across the esophagogastric junction (EGJ) and the 
propensity to develop hiatus hernia. However the causation is multifactorial 
and a single anatomical abnormality cannot account for GERD151. 
Increase in BMI has been shown to be associated with increase in 
prevalence of GERD symptoms, esophageal mucosal injury, and GERD 
complications by increased intra gastric pressure, GE pressure gradient, 
esophageal motor and sensory abnormalities, increase in prevalence of hiatus 
hernia, increase in serum female hormones, diet and increase in comorbidities. 
It is highly likely that multiple factors contribute to the prevalence of GERD in 
the obese patient152. 
Abdominal obesity rather than BMI is an independent risk factor for 
erosive esophagitis in the Korean population153. 
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Obesity, especially abdominal obesity, was the significant risk factor for 
erosive esophagitis154.  When 3363 patients who had GERD related esophagitis 
were analysed in a Korean study. 
Waist circumference, but not BMI, had some modest independent 
associations with the risk of Barrett's esophagus. The findings provide partial 
support for the hypothesis that abdominal obesity contributes to GERD, which 
may in turn increase the risk of Barrett's esophagus155. 
Weight loss, through caloric restriction and behavioral modification, has 
been studied infrequently as a means of improving reflux. Bariatric surgery and 
its effects on a number of obesity-related disorders have been studied more 
extensively. Roux-en-Y gastric bypass (RYGB) has been consistently 
associated with improvement in the symptoms and findings of GERD. The 
mechanism of action through which this surgery is successful at improving 
GERD may be independent of weight loss and needs further examination. 
Current evidence suggests that laparoscopic adjusted gastric banding should be 
avoided in these patients, as the impact on gastroesophageal reflux disease 
appears unfavorable156. 
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MATERIALS AND METHODS 
 
A total of 106 consecutive patients referred to the Gastroenterology unit 
with symptoms of  GERD were included in this study. The study period was 
from July 2007 to July 2008. 
Ethical committee approval and consent from the patients were 
obtained.  
 
STUDY DESIGN 
Prospective analysis of BMI, waist-hip ratio in patients with 
symptomatic GERD. 
 
SELECTION CRITERIA 
Consecutive patients attending gastroenterology outpatient department 
at Stanley Government Medical College Hospital for symptoms of GERD were 
included in the study. 
Patients who had dysmotility, those with history of abdominal surgery 
and pregnant women were excluded from this study. 
 
DEMOGRAPHIC DATA 
Total of 106 patients of which  45 were males and 61 females. 
Age ranged from 21 to 78 years. Mean age was 47.7 
Age and gender distribution of the study subjects are shown                   in 
Charts 1 & 2. 
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Symptoms  Defining Gastroesophageal Reflux Disease 
 
 
Classic symptoms of GERD such as heartburn and/or regurgitation,and 
other symptoms such as dysphagia, noncardiac chest pain, water brash, 
odynophagia, burping, bloating, early satiety, hiccups, nausea, vomiting, 
asthma, hoarseness of voice, chronic cough, recurrent lower respiratory 
symptoms, caries teeth, weight loss, upper GI bleed, and history of other 
comorbid illnesses especially related to obesity were recorded after direct 
questioning. 
History regarding diet habits such as intake of fatty food, fried food, 
spicy food, quantity of meals, excessive intake of citrus fruits, beverages such 
as coffee and tea, chocolates, aerated soft drinks, smoking, alcohol 
consumption, tobacco chewing, use of NSAIDs, oral contraceptives were 
recorded. 
History regarding radiation treatment, prolonged naso gastric aspiration 
and previous peptic ulcer disease were also recorded. 
 
Anthropometric Indices Were Recorded  
 
Weight was measured using a standard spring balance type of  weighing 
machine; height measured using a stadiometer on even ground; waist,hip 
circumference and abdominal girth were measured using a flexible nonelastic 
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type of measuring tape.   Abdominal girth was measured at the level of 
umbilicus in supine posture. Waist circumference was measured as the 
narrowest part of the torso in standing position and hip circumference as the 
widest part at the level of buttocks.  Waist hip ratio was calculated.             
BMI was calculated : weight(kg)/height(m2) 
Patients were then assigned to four categories according to their BMI. 
Statistical analysis was done for quantitative variables and expressed               
as mean +/- SD. 
The significance of differences in gender according to BMI, waist 
circumference and waist hip ratio were assessed using chi squared test. P value 
less than 0.05 was considered statistically significant. 
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RESULTS 
Of the 106 patients presenting with  GERD.  
52(49.1%) had BMI <23, out of which 14 were underweight and 38 
were of normal BMI.  
54(50.9%) had BMI >23, among which 22 were overweight and 32 
were obese. 
 
 
TABLE-1 : Table showing BMI distribution 
  
BMI <18.4 18.5 - 22.9 23 - 24.9 >25 
No. 14 38 22 32 
% 13.2 35.85 20.7 30.2 
 
If  the data  on gender were considered, females outnumbered male 
overweight and obese GERD patients. 
There were 40(65.6%) females vs 14(31.1%) males among GERD 
cases with BMI >23. 
 Odds ratio for obesity in females was 0.2 with 95% CI 0.1-0.5. 
 Risk ratio was 0.5 with 95% CI 0.3-0.8 
 Of the 45 males with GERD, 16(35.6%) had waist  circumference 
 >87cm, whereas 39(63.9%) out of 61 females had waist 
 circumference >82.  
 When waist hip ratio was calculated, 20(44.4%) out of 45 male 
 GERD patients were above 0.9 and 51(83.6%) out of 61 female 
 GERD patients were above 0.8. 
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The following table shows the gender based data for those who 
exceeded normal values of  BMI, waist circumference and waist-hip ratio. 
 
TABLE-2 :  Table showing comparison between male and female patients  
                      exceeding reference range for BMI, waist circumference and  
  waist- hip ratio  
 
 
Gender Total BMI >23 
% (No.) 
WC >87 & 82 cm  
% (No.) 
W-H R >0.9 & 0.8 
% (No.) 
Male 45 31.1%  
(14) 
35.6%  
(16) 
44.4%  
(20) 
Female 61 65.6 %  
(40) 
63.9%  
(39) 
83.6%  
(51) 
Pvalue  0.01 0.06 0.02 
 
The number of male GERD patients who were of <23 BMI(31) 
Were significantly more than those with BMI in overweight or 
obese category (14): P value 0.008. 
However the number of female GERD patients who were 
overweight or obese (40) exceeded those with BMI <23(14) P value 
0.02. 
The number of male GERD patients with waist circumference       
<87cms (29) were significantly more than those with higher waist       
circumference (16): P value 0.03, whereas the number of females                  
with waist circumference >82(39) were more than those within                  
normal range(22) but this value was not statistically significant. 
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The number of females(39) outnumbered the number of  Males (16) 
in the high waist circumference group but the difference was not 
statistically significant; the number of males (29) were more than 
females(22) in the normal waist  circumference group: P value 0.05. 
                  The number of male GERD patients who were within reference        
range for waist-hip ratio (25) were significantly more than those                  
with higher waist-hip ratios (20): P value 0.001. However the                  
number of female GERD patients with higher waist-hip ratios(51)                  
exceeded those within reference range(10): P value 0.006. 
    The number of females(51) were more than males(20) in the   
higher waist-hip ratio range: P value 0.02 whereas the number of                  
males (25) were more in the normal waist-hip ratio levels                  
compared to females(10): P value 0.01 
TABLE-3 : Table showing distribution of male GERD patients based on  
  BMI, waist circumference (WC) and waist-hip ratio(W-H R) 
 
 
 
 
 
 
 
 
 
 
 
BMI <23 >23 
No. 31 14 
WC <87cm >87cm 
No. 29 16 
W-H R <0.9 >0.9 
No. 25 20 
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TABLE-4 : Table showing distribution of female GERD patients based on  
BMI, waist circumference (WC) and waist-hip ratio (W-H R) 
 
BMI <23 >23 
No. 21 40 
WC <82cm >82cm 
No. 22 39 
W-H R <0.8 >0.8 
No. 10 51 
 
Upper GI endoscopy was done in 99 patients out of which there  
were 42 males and 57 females.  
Patients were classified as having erosive(ERD) vs  
nonerosive(NERD) reflux disease. 
There were more males with NERD than ERD; p value:0.03. 
There were more females with NERD than ERD; p value:0.07. 
Males were more likely to have ERD compared to females. 
OR:4.7 95% CI 1.6-13.6;pvalue:0.003. 
7 out of the 15 males with ERD were smokers. 
TABLE-5 : Table showing comparison between male and female patients  
  with NERD vs  ERD 
 
Variables NERD ERD 
Total No. 78 21 
Male 27 15 
Female 51 6 
BMI>23 44 10 
Male 8 6 
Female 36 4 
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56.4% of NERD patients were of BMI>23; 46.6% of ERD  
  patients were of BMI>23. 
Out of 78 patients with NERD 70.6% of females and 29.6% of  
males had BMI  >23.      
Out of 21 patients with ERD    66.6% of females and 40.0% of  
 males had BMI >23. 
 
Hiatus hernia was present in 13 patients out of which 7 were  
 males and 6 were females. 4 in each group had BMI >23 
 
TABLE-6 : Table showing distribution of Hiatus hernia  
 
Variables No. % (no.) 
BMI>23 
% (no.) 
WC>87/82 
% (no.) W-H 
R>0.9/0.8 
Total 13 61.5% (8) 92.3% (12) 84.6% (11) 
Male 7 57.1% (4) 85.7% (6) 71.4% (5) 
Female 6 66.7% (4) 100% (6) 100% (6) 
 
  
Lax LES was present in 6 males and 5 females, out of which 1 male and 4 
females had BMI >23 . 
 
TABLE-7 : Table showing distribution of Lax LES 
 
Variables No. % (no.) 
BMI>23 
% (no.) 
WC>87/82 
% (no.)  
W-H R>0.9/0.8 
Total 11 45.4% (5) 45.4% (5) 63.6% (7) 
Male 6 16.7% (1) 16.7% (1) 50% (3) 
Female 5 80% (4) 80% (4) 80% (4) 
 
 
 
 
 
 
 
 
 
Chart – 1    
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SUMMARY 
 
 A total of 106  GERD patients were analysed for prevalence of  
obesity by measures such as BMI, waist circumference and waist-
hip ratio. 
 There were 45 males and 61 females. 
 BMI was >23 in 54 of 106 patients:50.9% 
 There were significantly more females  with high BMI and waist- 
  hip ratio compared to males; however the gender difference was  
  not statistically significant based on waist circumference. 
 The number of males with BMI, waist circumference and waist- 
  hip ratio less than cutoff value for obesity were significantly  
  more than obese males. 
 The number of females with BMI and waist-hip ratio more than  
  cutoff value for obesity were significantly more than nonobese  
  females; however, the difference between obese and nonobese  
  female patients based on waist circumference was not statistically  
  significant. 
 99 patients underwent UGI endoscopy. 
 NERD was more prevalent than ERD in both males and females. 
 Males were more likely to have ERD compared to females. 
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DISCUSSION 
 
Association Between Obesity And Gerd 
Gastro esophageal reflux disease is a multifactorial process resulting 
from an imbalance between defensive factors (antireflux barriers, esophageal 
acid clearance,tissue resistance) and aggravating factors (gastric acidity,volume 
and duodenal contents). Obesity satisfies several criteria for a causal 
association with GERD and abdominal obesity impairs antireflux function by 
increasing intragastric pressure, gastroesophageal gradient,TLOSR and 
esophageal acid exposure. 
 El-Serag157 reviewed epidemiological data to find a consistent 
association of obesity with GERD symptoms, erosive esophagitis and 
esophageal adenocarcinoma. 
 The Asia Pacific consensus update states that GERD is increasing in 
frequency in Asia. Risk factors include increased body mass index. Weight loss 
improves reflux symptoms123  
 
Factors Defining Obesity 
BMI has been widely used as an indicator of adiposity; its limitations 
have been widely recognized by its dependence on race: Asians have larger 
percentage of body fat at lower BMI values.As compared to BMI, waist 
circumference and waist-hip ratio have been used as surrogates of body fat 
centralization.Many studies such as the INTERHEART  have proposed the use 
of waist circumference and waist-hip ratio as markers of obesity rather than 
BMI. 
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In this study, obesity was defined according to the WHO cutoff as BMI 
>25 and overweight as BMI >23 irrespective of gender102 
Waist circumference and waist-hip ratio cut points were defined as >87 
in males, >82 in females and >/=0.9 in males and >/=0.8 in females 
respectively as per current recommendations for urban Asian Indians158 
 
Age Distribution 
The age range of 106 consecutive patients with GERD was 21-78, mean 
age was 47.7  Age distribution is shown in Chart-1 
Gender Distribution 
There were 58% females and 42% males. Dore MP et al report a similar 
gender distribution with 66% females vs 48% males in their cohort148.   Female 
preponderance has been noted in various studies possibly due to the effect of 
Estrogen131,132,133,159.  Gender distribution is shown in Chart-2. 
BMI Distribution 
The BMI values in this group ranged from 15.2-35.4 with mean BMI  
22.7 and median BMI 23.0  as compared to the BMI range of 16-52 in a 
western cohort with mean BMI 27.5 and median BMI 27 in a study by El-Serag 
et al in USA159.  The lower mean BMI in Asian population argues against the 
use of same BMI cutoff values for different ethnic 
populations101,102,103,104,105,106,158.  The patients were classified according to their 
BMI as thin (<18.5) who were 13.2%, normal(18.5-23) with 35.85%, 
overweight(23-25) with 20.75% and obese(>25) with 30.2% of the patients. 
The BMI distribution in this study is represented in Chart-3. 
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The BMI distribution of patients in a study by  Sakaguchi et al128 in 
Japan showed 20.96% in the thin group which is marginally more than this 
study. The patients in normal BMI group was 24.42% which was less 
compared to this study. The patients with BMI >23 who were overweight and 
obese were 31.86% in the Japanese study whereas those with BMI >23 were 
50.95% in this study. 
A Korean study which classified GERD patients as per western 
standards found the distribution to be BMI <25 (68.9%), 25-30(28.7%) and 
>30(2.4%)153. 
Corley DA et al found an odds ratio of 1.52 for overweight and 2.15 for 
obese group for risk of GERD in a meta-analysis of studies within the USA11. 
whereas a study in Asians in Korea found an odds ratio of 1.2 for overweight 
and 1.9 for obese patients with GERD160. 
The age-wise mean BMI was analysed and the mean BMI was highest in 
the 50-59 age group (25.41) of patients while the most number of patients with 
GERD was found in the 40-49 age group (n35) in this study. In Locke et al 
study in USA114 the mean age was 50 and <24 BMI group were 15%, 
overweight were 37% and obese were 30% similar to this study with obese 
30.2%. 
 
Gender Differences in BMI Distribution 
 Female GERD patients in all age groups had higher mean BMI 
compared to males, the highest mean BMI(28.24) was observed in 50-59 age 
group. 
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The number of female overweight and obese GERD patients were more 
than males in the same BMI group: 40(65.6%) vs 14(31.1%).The difference 
was statistically significant.P value 0.01 This is supported by a study in Italy by 
Piretta L et al who found increased prevalence of overweightedness and obesity  
in females with GERD132 
The gender difference based on BMI is shown in Charts 4 & 5. 
The number of obese females having GERD based on BMI was 
significantly more than nonobese females.40(65.6%) vs 21(34.4%).                  
P value 0.02. 
The converse was true for males,with 14(31.1%) in obese group vs 
31(68.9%) in nonobese group. P value 0.008.  
 
Waist circumference and waist-hip ratio as risk factors for GERD: 
The prevalence of obesity was more based on waist circumference  
(51.9%) and waist-hip ratio  (67%) than BMI  (30.2%) in this study 
Many studies have shown a positive correlation for waist circumference 
with reflux disease. El-Serag et al have correlated waist girth with increased 
intragastric pH.159 
Corley DA et al found correlation of symptoms with abdominal girth in 
among whites but not blacks or Asians in USA121 and symptom severity 
increased with abdominal girth155 and the odds ratio was 1.86, 
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When gender specific data were considered, females with higher waist 
circumference were more than males: 39(63.9%) vs 16(35.6%) P value 0.06 but 
the difference was not statistically significant. 
Females with waist-hip ratio above cutoff levels were more than males: 
51(83.6%) vs 20(44.4%) with significant difference: P value 0.02 
The number of obese females based on waist-hip ratio was significantly 
more than nonobese females in this study: 51(83.6%) vs 10(16.4%)                  
P value 0.006. 
Endoscopy Findings 
 
The 99 patients who underwent endoscopy were classified as 
erosive(ERD) and non-erosive reflux disease(NERD).  
In this study 78 patients(78.8%) had NERD and 21(21.2%) had ERD.  
15(35.7%) out of 21 patients with ERD were males with odds ratio 4.7 (95% 
CI: 1.6-13.6) P value 0.005. 
NERD was more prevalent than ERD in both males and females. 
This was comparable to an Asian endoscopy based study by Rosaida 
MS  et al who have shown a similar incidence of NERD 65.5% and ERD 
13.4%126  
Male Gender As a Risk For ERD 
Rosaida MS et al126 have found male gender being a risk factor for ERD. 
Moki F et al also found males to be at risk for ERD with odds ratio 2.5 and 
obesity to be associated with ERD; odds ratio 1.9161 
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Nocon et al found obese women to be at risk for ERD compared to 
nonobese women with odds ratio 2.5 but in the present study this difference 
was not statistically significant.130 
Obesity as A Risk For ERD 
Zafar et al found endoscopic severity to correlate with BMI in 203 
subjects in a study in Pakistan162 
Wilson et al found BMI to correlate with ERD: odds ratio 1.8138. 
Some studies have found waist hip ratio to be a risk factor for ERD154 with 
odds ratio 2.3. 
In a Korean study Kang MS et al found abdominal obesity rather than 
BMI to correlate with risk for ERD: odds ratio 2.3 The prevalence of 
abdominal obesity in this study was 24.2% and ERD was 6.6%153 
In the present study there was no significant correlation between obesity 
and ERD with BMI, waist circumference or waist-hip ratio as criteria for 
obesity in either gender although the prevalence of ERD was 21.2% of the 99 
patients who underwent UGI endoscopy. 
 
Hiatus Hernia and GERD 
 
Hiatus hernia was present in 13(13.1%) patients.Rosaida MS et al have 
reported a prevalence of 6.7% in their group in Malaysia126 
Wilson LJ et al have reported an association between hiatus hernia and 
risk of ERD with odds ratio 4.2138  
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In the present study 5 patients had hiatus hernia among the 21 with 
ERD. The odds ratio was 2.7 but the association was not statistically 
significant. 
 
Table showing comparison of previous studies with present study 
 
Variables Previous studies Present study 
AGE 
 
  Range 
   
  Mean 
 
GENDER 
 
  Females 
 
  Males 
 
BMI 
 
  Range 
 
  Mean 
 
BMI Distribution 
 
  Thin                <18.5 
  Normal           18.5-23 
  Overweight    23-25 
  Obese             >25 
 
OBESITY 
 
NERD 
 
ERD 
 
MALE GENDER as risk for ERD 
HIATUS HERNIA 
HIATUS HERNIA as risk for ERD 
 
 
 
 
50 (Locke114) 
 
 
 
66% (Dore148) 
 
48%    ’’ 
 
 
 
16-42 (El-Serag159 
 
27.5      ” 
 
 
 
20.9% (Sakaguchi128) 
24.42%        ” 
 
    31.86%        ” 
 
30% (Locke114) 
 
65.5% (Rosaida126) 
 
13.4%       ” 
 
OR 2.5 (Moki161) 
6.7% (Rosaida126) 
OR 4.2 (Wilson138) 
 
 
21-78 
 
47.7 
 
 
 
58% 
 
42% 
 
 
 
15.2-35.4 
 
23.0 
 
 
 
13.2% 
35.85% 
20.75% 
30.2% 
 
30.2% 
 
78.8% 
 
21.2% 
 
4.7 
13.1% 
2.7 
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CONCLUSIONS 
 
 
 
 This study adds to a growing body of literature that strongly  
 suggests an association between obesity and gastroesophageal  
 reflux disease. 
 Prevalence of obesity among patients with GERD was more  
 based on waist circumference and waist-hip ratio than BMI. 
 The link between obesity and GERD is stronger in women. 
 
Implications of this study is that: 
 
a) Clinicians should ask about symptoms of GERD when assessing the 
health risks in overweight and obese patients. 
b) Weight reduction should be advised in those with reflux symptoms as 
Barrett’s esophagus and esophageal cancer are known risks of long 
standing reflux. 
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ABBREVIATIONS 
 
BMI     body mass index 
Oe N/I/E/U                   oesophagus normal/ inflammation/erosion/ulcer 
St N/I/E/U                     stomach normal/inflammation/erosion/ulcer 
Du N/I/E/U                   duodenum normal/inflammation/erosion/ulcer 
M                                   male 
F                                    female 
abd girth                        abdominal girth 
W-H ratio                      waist-hip ratio 
NV/week                       nonvegetarian diet:no. of times per week 
NSAID                          nonsteroidal anti-inflammatory drugs 
NG aspir                        nasogastric aspiration 
D/N                                day/night 
D/Occ                            daily/occasionally 
D/W/M                          daily/weekly/monthly 
int/cont                          intermittent/continuous 
sol/liq                            solids/liquids 
rec LRI                          recurrent lower respiratory infections 
UGI                               upper gastrointestinal 
     77 
MGE  No.                      medical gastroenterology serial number 
L S mod                         life style modification 
Resp to Rx                       response to therapy 
rec                                    recurrence of symptoms on stopping treatment 
lax LES                            laxity of lower esophageal sphincter 
DM                                   diabetes mellitus 
Htn                                     hypertension 
Hypothyr                            hypothyroidism 
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P R O F O R M A 
 
 1.  Name    :      
 2.  Age    : 
 3.  Gender    :  Male / Female 
 4.  Occupation   : 
 5.  Address    : 
 6.  M.G.E No.   : 
 7.  Height    : Cms 
 8.  Weight    : Kgs 
 9.  BMI    : 
10. Abdominal girth   : 
11. Waist-hip ratio   : 
12. Smoking    :  Yes / No No.  Years 
13. Tobacco chewing  :  Yes / No 
14. Alcohol use   :  Yes / No Frequency  Duration 
15. Diet    :  Veg. / Non.Veg Non.Veg. No.of 
times/week 
16. Fried food   :  Yes / No No. of times/week 
17. Type of Food   :  Bland/Mildly spicy/moderately spicy/very 
spicy 
18. Quality of Food   :  Small / Moderate / Large 
19. Citrus fruits   :  Yes / No 
20. Fatty Food   :  Yes / No 
21. Chocolates   :  Yes / No     
22. Coffee / Tea   :  Yes / No    No.of times/day 
23. Aerated/Soft drinks  :  Yes / No    No.of times/day 
24. NSAID use   :  Yes / No 
25. Pill    :  Yes / No 
26. Infection    :  Yes / No 
27. Radiation    :  Yes / No 
     79 
28. Pregnancy   :  Yes / No 
29. Prolonged NG aspiration :  Yes / No 
30. Peptic Ulcer / ZES  :  Yes / No 
31. Scleroderma   :  Yes / No  
32. Heartburn   :  Duration  
        Day / Night / both 
        Everyday / No.of times/day:      /week:         
/Month 
        Supine / bending over / sitting 
33. Regurgitation   :  Yes / No 
         Duration 
    Day / Night / both 
         Everyday / No.of times/day:      /week:         
/Month 
         Supine / bending over / sitting 
         Post meal regurgitation:        Yes / No 
34. Dysphagia   :  Yes / No 
         Intermittent / continuous 
         Solids / Liquids / Both 
35. Chest pain   :  Yes / No 
         Duration 
         Frequency 
                   Severity 
         Related to meal :     Yes / No 
                          Stress:    Yes / No 
                                                                             Sleep:    Yes / No     
        Relief: Spontaneous/Anatacids/PPI/H2RA 
36. Water brash   :  Yes / No        
37. Odynophagia   :  Yes / No        
38. Burping    :  Yes / No        
39. Bloating    :  Yes / No        
     80 
40. Early satiety   :  Yes / No        
41. Hiccups    :  Yes / No        
42. Nausea    :  Yes / No        
43. Vomiting    :  Yes / No        
44. Asthma    :  Yes / No        
45. Hoarseness of voice  :  Yes / No        
46. Chronic cough   :  Yes / No        
47. Recurrent LRI   :  Yes / No        
48. Caries teeth   :  Yes / No        
49. Weight loss   :  Yes / No        
50. UGI Bleed   :  Yes / No 
 
INVESTIGATIONS: 
51. Endoscopy No.   : 
      Result :  Normal / Edema / Erythema / Friability / Red streaks / erosions / 
Ulcers 
52. Barium study   : 
53. Therapy    : 
53.1  Change in diet   :             Yes / No 
53.2  Relief with raising head-end of bed :  Yes / No 
53.3  Antacids    :       Yes / No 
53.4  H2RA     :       Yes / No 
53.5  PPI     :       Yes / No 
54. Recurrence of symptoms on stopping drugs: Yes / No 
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1 2249/02 62 F housewife Chennai 155 56 23.31 81 88/97 0.91 No Yes No 3 1 spicy moderate
2 5792/02 67 F housewife Chennai 148 51 23.28 84 85/100 0.85 No No No 1 1 spicy moderate
3 6251/02 34 M driver Chennai 158 50 20.03 77 78/87 0.89 No No No 1 1 spicy moderate
4 6357/02 49 M security Chennai 178 51 16.09 67 71/85 0.80 Yes No Yes 2 2 spicy moderate
5 1334/03 71 F housewife Chennai 147 41 18.97 78 72/90 0.80 No No No 1 >3 spicy moderate
6 2779/03 46 M driver Chennai 162 40 15.24 64 62/74 0.83 Yes No Yes >3 >3 spicy large
7 3605/03 78 M - Chennai 164 45 16.73 71 73/84 0.86 Yes No Yes 2 >3 spicy large
8 4858/03 68 F housewife Chennai 142 53 26.28 87 88/100 0.88 No No No 2 2 spicy moderate
9 302/03 46 F housewife Chennai 150 68 30.22 97 98/111 0.88 No No No 1 <3 spicy moderate
10 2806/04 62 F maid Chennai 149 44 19.82 74 84/92 0.91 No No No 3 >3 spicy moderate
11 3780/04 62 F maid Chennai 144 54 26.04 94 94/102 0.92 No Yes No 3 <3 spicy large
12 4005/04 35 F housewife Chennai 152 61 26.40 82 89/98 0.90 No No No 0 0 spicy large
13 4095/04 41 M - Chennai 177 58 18.51 74 81/91 0.89 No Yes No 2 0 spicy moderate
14 4729/04 50 M clerk Chennai 162 66 25.15 91 87/97 0.89 Yes No No 3 >3 spicy moderate
15 5995/04 74 F housewife Chennai 144 44 21.22 74 78/84 0.93 No Yes No 0 0 spicy moderate
16 754/05 45 F housewife Chennai 161 60 23.15 78 82/95 0.86 No Yes No 1 2 spicy large
17 1068/05 52 F housewife Chennai 146 75 35.18 93 96/112 0.86 No No No 1 <3 spicy moderate
18 1106/05 55 M security Chennai 165 65 23.87 96 93/97 0.96 No Yes Yes 0 0 spicy moderate
19 2599/05 60 F housewife Chennai 154 46 19.39 86 89/91 0.98 No No No 2 <3 spicy large
20 2754/05 45 F housewife Chennai 151 69 30.26 94 93/106 0.88 No No No 3 <3 spicy large
21 2936/05 45 F labourer Chennai 153 48 20.50 67 70/87 0.80 No No No 1 <3 spicy large
22 3661/05 60 F housewife Chennai 140 50 25.51 82 85/99 0.86 No No No 1 <3 spicy moderate
23 3916/05 33 F housewife Chennai 149 54 24.32 77 77/93 0.83 No No No 3 >3 spicy moderate
24 4789/05 48 F maid Chennai 150 47 20.89 83 85/95 0.89 No No No 2 <3 spicy moderate
25 Fathima 50 F housewife Chennai 147 60 27.77 80.5 87/92 0.94 No No No >3 >3 spicy moderate
26 713/06 45 M security Chennai 155 52 21.64 76 82/93 0.88 No No No 1 1 spicy moderate
27 847/06 42 F housewife Chennai 146 49 23.00 81 82/90 0.91 No No No 3 3 spicy moderate
28 972/06 54 M labourer Chennai 166 53 19.23 80 83/89 0.93 Yes No No 1 0 spicy moderate
29 1397/06 40 F housewife Chennai 149 42 18.92 64 67/87 0.77 No No No 1 spicy small
30 1780/06 50 F housewife Chennai 150 57 25.33 83 85/102 0.80 No No No 2 2 spicy moderate
31 2331/06 37 F labourer Chennai 168 66 23.38 83 86/94 0.90 No No No 2 <3 spicy moderate
32 2470/06 60 F housewife Chennai 152 40 17.31 66 65/90 0.70 No No No 1 0 spicy moderate
33 3036/06 54 M marketing Chennai 158 61 24.43 91 92/99 0.90 No No No 1 >3 spicy moderate
34 3090/06 42 M labourer Chennai 164 52 19.33 76 78/83 0.94 Yes No Yes 3 <3 spicy moderate
35 4340/06 39 M labourer Chennai 178 61 19.25 76 76/96 0.79 Yes Yes Yes 3 3 spicy large
36 4829/06 40 F housewife Arcot 157 62 25.15 84 83/106 0.78 No No No 0 0 spicy moderate
37 5200/06 29 M driver Chennai 168 53 18.79 72 75/85 0.88 No No Yes >3 >3 spicy moderate
38 5248/06 50 M labourer Chennai 169 66 23.11 85 87/96 0.91 Yes Yes Yes 3 >3 spicy large
39 5284/06 50 F vendor Chennai 145 42 19.97 84 74/93 0.79 No No No 1 >3 spicy moderate
40 5293/06 33 F maid Chennai 157 60 24.34 87 72/102 0.90 No No No 1 <3 spicy moderate
41 6224/06 44 F housewife Chennai 155 76 31.63 94 93/110 0.84 No No No 1 <3 spicy large
42 6294/06 39 F housewife Chennai 147 34 15.73 63 64/75 0.85 No No No 1 >3 spicy small
43 6352/06 32 M driver Chennai 170 75 25.95 88 90/100 0.90 No No Yes 3 <3 spicy moderate
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44 6911/06 35 F labourer Chennai 160 59 23.05 82 85/100 0.85 No No No 1 <3 spicy moderate
45 7072/06 45 F cowherd Chennai 160 46 17.97 67 70/93 0.75 No No No 1 >3 spicy large
46 7182/06 65 F housewife Chennai 162 69 26.29 94 91/104 0.87 No No No 1 0 spicy large
47 210/07 70 M - Chennai 170 67 23.18 93 93/99 0.94 No Yes No 2 >3 spicy large
48 287/07 45 F housewife Chennai 166 47 17.06 68 66.5/99 0.67 No No No 2 >3 spicy moderate
49 1108/07 60 M security Chennai 164 72 26.77 102 97/104 0.90 Yes Yes Yes 3 0 spicy moderate
50 1175/07 43 F housewife Chennai 154 50 21.08 75 74/91 0.81 No No No 3 <3 spicy moderate
51 1776/07 46 F housewife Chennai 156 51 20.96 77 82/90 0.90 No Yes No 2 3 spicy large
52 1958/07 28 M clerk Chennai 163 42 15.81 60 61/75 0.80 Yes No No 1 0 spicy moderate
53 1802/07 63 F housewife Chennai 154 56 23.61 85 86/102 0.80 No Yes No 3 <3 spicy moderate
54 1830/07 57 M clerk Chennai 170 56 19.38 84 83/93 0.89 No No No 0 <3 spicy moderate
55 1871/07 30 M labourer Chennai 175 66 21.55 84 87/98 0.89 No No No 1 >3 spicy moderate
56 2121/07 38 F housewife Chennai 158 45 18.02 74 73/87 0.84 No No No 2 2 spicy moderate
57 2392/07 51 M labourer Chennai 165 63 23.14 84 83/93 0.89 Yes No Yes 1 0 spicy moderate
58 3036/07 45 M labourer Chennai 168 52 18.42 69 69/85 0.80 No No No 2 0 spicy moderate
59 3081/07 32 M labourer Chennai 164 52 19.33 71 77/86 0.89 No Yes Yes >3 >3 spicy large
60 3142/07 23 F marketing Chennai 150 54 24.00 84 81/95 0.85 No No No 1 1 spicy moderate
61 3213/07 70 M - Chennai 164 65 23.30 97 94/108 0.87 No No No 3 <3 spicy moderate
62 3217/07 50 F housewife Chennai 155 68 28.30 98 99/107 0.89 No No No 1 0 spicy moderate
63 3434/07 44 F housewife Chennai 160 70 27.34 95 99/109 0.90 No No No 2 ,3 spicy moderate
64 3477/07 41 M clerk Chennai 167 53 19.00 82 83/91 0.90 Yes Yes Yes 3 >3 spicy moderate
65 3597/07 45 F housewife Chennai 148 57 26.02 82 84/104 0.80 No No No 1 0 spicy small
66 3958/07 61 M - Chennai 174 62 20.48 85 88/95 0.90 No No Yes 2 0 spicy moderate
67 4109/07 55 M - Chennai 167 59 21.16 87 92/94 0.97 No Yes Yes 1 <3 spicy moderate
68 4596/07 38 M security Chennai 166 60 21.77 87 88/96 0.90 No No No 1 0 spicy large
69 /07 60 F housewife Chennai 143 53 25.92 86 88/101 0.87 No No No 2 >3 spicy moderate
70 4983/07 36 M labourer Chennai 170 70 24.22 88 95/100 0.95 No No No 2 <3 spicy large
71 5012/07 50 F housewife Chennai 152 76 32.68 103 104/117 0.89 No No No 2 2 spicy moderate
72 5072/07 48 F housewife Chennai 150 52 23.11 76 71/91 0.78 No No No 2 >3 spicy moderate
73 5318/07 75 M - Chennai 164 56 20.82 82 80/91 0.88 Yes No No 1 0 spicy moderate
74 6133/07 35 M marketing Chennai 160 66 25.78 89 93/102 0.90 Yes Yes Yes 3 >3 spicy moderate
75 6142/07 59 F housewife Chennai 154 62 26.14 92 98/105 0.90 No No No 2 1 spicy moderate
76 6194/07 45 F housewife Chennai 155 51 21.23 80 82/98 0.80 No No No 1 >3 spicy moderate
77 6480/07 65 F housewife Chennai 134 34 18.93 68 73/85 0.86 No No No 2 2 spicy moderate
78 6760/07 45 M labourer Chennai 164 65 24.17 84 86/96 0.89 Yes No No 3 3 spicy large
79 6875/07 50 F housewife Chennai 149 65 29.28 89 88/108 0.80 No No No 2 1 spicy large
80 7066/07 56 M - Chennai 165 50 18.36 74 78/84 0.90 Yes No No 1 1 spicy large
81 7195/07 40 M labourer Chennai 169 54 18.91 74 80/87 0.90 No No No 3 <3 spicy moderate
82 52/08 60 F maid Chennai 149 52 23.42 79 80/96 0.80 No Yes No 1 <3 spicy moderate
83 342/08 47 F housewife Chennai 156 64 26.29 91 89/104 0.85 No Yes No 4 >3 spicy large
84 361/08 29 F maid Chennai 156 62 25.47 96 86/103 0.80 No No No 3 3 spicy large
85 554/08 45 M labourer Chennai 162 57 21.72 81 84/94 0.89 Yes No Yes 7 >3 spicy large
86 907/08 55 F labourer Chennai 155 85 35.38 100 105/120 0.87 No No No 1 0 spicy moderate
87 927/08 50 F housewife Chennai 150 60 26.66 78 78/100 0.78 No No No 1 1 spicy large
88 1270/08 21 M vendor Chennai 169 54 18.91 65 69/86 0.80 No No Yes 1 <3 spicy large
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89 1478/08 53 F maid Chennai 153 56 23.92 78 85/95 0.89 No No No 1 >3 spicy large
90 1738/08 38 F labourer Chennai 154 67 28.25 86 94/113 0.80 No Yes No >3 >3 spicy large
91 1910/08 28 F housewife Chennai 157 50 20.28 72 74/89 0.80 No No No 1 >3 spicy moderate
92 2209/08 65 M - Chennai 168 56 19.84 84 86/90 0.98 Yes No No 1 0 spicy large
93 2282/08 43 F housewife Chennai 144 48 23.15 76 76/96 0.79 No No No 2 3 spicy moderate
94 2455/08 28 F housewife Chennai 155 50 20.81 74 74/89 0.80 No No No 1 0 spicy large
95 2640/08 40 M labourer Chennai 170 60 20.76 83 85/92 0.90 Yes Yes Yes >3 >3 spicy large
96 2814/08 20 M - Chennai 170 62 21.45 70 72/88 0.80 No No No 1 1 spicy large
97 2868/08 40 F labourer Chennai 150 59 26.22 84 85/100 0.85 No No No 1 <1 spicy moderate
98 2927/08 40 M labourer Chennai 168 47 27.98 65 65/79 0.80 Yes No No 1 0 spicy moderate
99 2956/08 47 F housewife Chennai 157 67 27.18 85 85/102 0.80 No No No 1 0 spicy moderate
100 3112/08 52 M security Chennai 157 71 28.80 100 100/97 1.03 No No No 1 1 spicy large
101 3565/08 23 M driver Chennai 175 51 16.65 67 68/78 0.87 Yes Yes No 1 1 spicy moderate
102 62588 62 F housewife Chennai 150 48 21.33 80 85/97 0.88 No No No 2 0 spicy large
103 108/08 55 M labourer Chennai 170 63 21.79 87 90/97 0.90 Yes No No 2 2 spicy moderate
104 3353/08 44 M labourer Chennai 155 40 16.65 63 67/89 0.80 Yes Yes Yes 3 3 spicy moderate
105 2653/08 62 M - Chennai 165 49 17.99 72 74/85 0.87 No No No 2 >3 spicy moderate
106 3355/08 47 F labourer Chennai 153 36 15.38 61 59/78 0.76 No No No 3 3 spicy moderate
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1 Yes No Yes 1 Yes Yes No No No No No No Yes 6 months D D Yes 6 monnths D D
2 No Yes No 2 No No No No No No No No Yes 3 months D D Yes 3 months D D
3 No No No 3 Yes Yes No No No No No No Yes 6 yrs D rare Yes 6 yrs D M
4 Yes Yes Yes 2 Yes No No No No No No No No Yes 3 yrs D W
5 Yes No No 2 No Yes No No No No No No Yes 1 yr Both D Yes 1 yr Both D
6 Yes Yes No 4 Yes Yes No No No No No No Yes 5 yrs Both D Yes 5 yrs D D
7 Yes Yes No 3 No No No No No No No No No Yes 5 months Both W
8 Yes No No 2 Yes Yes No No No No No No No Yes 6 yrs D W
9 Yes Yes No 2 Yes Yes No No No No No No Yes 4 yrs D occ Yes 4 yrs D D
10 Yes No Yes 4 Yes No No Yes No No No No Yes 2 yrs D D Yes 2 yrs D D
11 Yes Yes No 2 Yes No No No No No No No Yes 4 yrs Both D Yes 4 yrs Both D
12 Yes No No 1 No No No No No No No No Yes 4 yrs N D No
13 No No No 6 Yes Yes No No No No No No Yes 4 yrs D D No
14 Yes Yes Yes 3 No No No No No No No No Yes 10 days D D Yes 10 days D D
15 No No No 2 Yes No No No No No No No Yes 4 yrs Both D Yes 4 yrs Both D
16 No Yes No 2 Yes Yes No No No No No No Yes 4 yrs Both D Yes 4 yrs Both D
17 Yes Yes No 2 No No No No No No Yes No Yes 3 yrs Both D Yes 3 yrs Both D
18 No No No 2 No No No No No No No No Yes 5 yrs Both D No
19 No No No 2 No No No No No No No No Yes 4 months Both D No
20 Yes Yes No 5 Yes Yes No No No No No No Yes 2.5 yrs Both D Yes 2.5 yrs Both D
21 No No No 1 No Yes No No No No No No No Yes 3 months Both D
22 Yes No Yes 2 Yes Yes No No No No No No Yes 1 month D occ Yes 1 month Both D
23 No Yes Yes 2 Yes Yes No No No No No No Yes 3 yrs Both D Yes 3 yrs D D
24 Yes No No 3 Yes Yes No No No No No No Yes 3.5 yrs Both occ Yes 3.5 yrs Both W
25 No Yes No 3 No No No No No No No No Yes 5 yrs Both D Yes 5 yrs Both D
26 Yes Yes No 2 Yes Yes No No No No No No Yes 3 yrs D D Yes 3 yrs D D
27 No Yes No 2 Yes Yes No No No No No No Yes 2 months Both D Yes 2 months Both D
28 No No No 10 No No No No No No No No Yes 1 month D D Yes 1 month D D
29 Yes No No 4 Yes No No No No No No No Yes 5 yrs Both occ Yes 3 months Both W
30 No Yes No 0 Yes No No No No No No No Yes 2 yrs D D Yes 2 yrs D D
31 Yes Yes No 4 Yes Yes No No No No No No Yes 2.5 yrs Both occ Yes 6 monnths D W
32 Yes No No 0 No No No No No No No No Yes 5 yrs Both D No
33 Yes Yes Yes 4 Yes No No No No No No No Yes 2 yrs Both D Yes 2 yrs N D
34 Yes Yes No 10 No No No No No No No No Yes 1.5 months D D No
35 Yes No No 1 Yes Yes No No No No No No Yes 3 yrs Both D Yes 3 yrs Both D
36 No No No 3 No Yes No No No No No No Yes 2.5 yrs D occ Yes 2.5 yrs D W
37 Yes Yes No 3 Yes Yes No No No No No No Yes 1 yr D D Yes 1 yr Both D
38 Yes Yes Yes 2 Yes No No No No No No No Yes 3 months D D Yes 3 months D D
39 No No Yes 2 No No No No No No No No Yes 2 yrs Both rare Yes 2yrs D M
40 No No No 1 Yes No No No No No No No No Yes 2 yrs D M
41 Yes Yes No 2 No Yes No No No No No No Yes 1.5 yrs D occ No
42 Yes No No 3 Yes Yes y No No No No No Yes 3 yrs D D Yes 3 months D W
43 Yes No No 1 No No No No No No No No Yes 2 yrs D D Yes 2 yrs D D
Sl
.
N
o
c
i
t
r
u
s
f
r
u
i
t
f
a
t
c
h
o
c
o
l
a
t
e
c
o
f
f
e
e
/
t
e
a
s
o
f
t
d
r
i
n
k
N
S
A
I
D
P
i
l
l
i
n
f
e
c
t
i
o
n
r
a
d
i
a
t
i
o
n
p
r
e
g
n
a
n
t
N
G
 
a
s
p
i
r
S
c
l
e
r
o
d
e
r
m
H
e
a
r
t
b
u
r
n
d
u
r
a
t
i
o
n
D
/
N
/
B
o
t
h
D
/
o
c
c
/
r
a
r
e
R
e
g
u
r
g
d
u
r
a
t
i
o
n
D
/
N
/
B
o
t
h
D
/
W
/
M
44 Yes Yes No 2 Yes Yes No No No No No No Yes 3 months Both D Yes 3 months Both D
45 No No No 2 Yes Yes No No No No No No Yes 1 yr Both D Yes 1 yr D D
46 No No No 2 No Yes No No No No No No No Yes 1 yr Both D
47 Yes Yes Yes 3 Yes Yes No No No No No No Yes 2 yrs Both D No
48 No Yes No 5 No No No No No No No No Yes 1 yr D rare Yes 1 yr D W
49 No No No 3 No Yes No No No No No No Yes 2 yrs D occ No
50 No No Yes 3 No Yes No No No No No No Yes 2 months D D Yes 2 months night D
51 No No No 2 No Yes No No No No No No Yes 3 months Both D Yes 3 months Both D
52 Yes No No 3 No No No No No No No No Yes 3 months Both D Yes 3 months Both D
53 No No No 4 Yes Yes No No No No No No Yes 2.5 yrs D D Yes 2.5 yrs D D
54 Yes No No 3 Yes Yes No No No No No No Yes 1.5 yrs D D Yes 1.5 yrs D D
55 No No Yes 0 Yes Yes No No No No No No Yes 1.5 yrs Both D Yes 1 yr Both D
56 No No No 2 No Yes No No No No No No Yes 2 yrs D D Yes 2 yrs D W
57 Yes Yes Yes 3 No No No No No No No No Yes 3 yrs Both D Yes 3 yrs Both D
58 Yes No No 2 No Yes No No No No No No Yes 3 months D D Yes 3 months D D
59 Yes No Yes 5 No Yes No No No No No No No Yes 1 yr D W
60 Yes Yes Yes 0 Yes Yes No No No No No No Yes 2 yrs Both D Yes 2 yrs D D
61 No Yes No 2 No No No No No No No No Yes 1.5 yrs N D Yes 1.5 yrs Both D
62 Yes No No 0 Yes Yes No No No No No No Yes 1.5 yrs Both W Yes 1.5 yrs D D
63 Yes Yes No 2 No Yes No No No No No No Yes 1 yr Both D Yes 1 yr D D
64 Yes Yes Yes 0 No Yes No No No No No No Yes 8 months D D No
65 No No No 2 Yes No No No No No No No Yes 1.5 yrs D D Yes 1.5 yrs Both D
66 Yes No No 4 No Yes No No No No No No Yes 4 yrs N D Yes 4 yrs N D
67 Yes Yes No 8 Yes Yes No No No No No No Yes 2 yrs Both D Yes 2 yrs Both D
68 Yes No No 2 Yes Yes No No No No No No Yes 2.5 yrs Both W Yes 2.5 yrs Both W
69 Yes Yes Yes 2 Yes Yes No No No No No No No Yes 7 months D D
70 Yes No No 3 No Yes No No No No No No Yes 3 months N W No
71 Yes Yes Yes 1 Yes Yes No No No No No No Yes 1 yr Both W Yes 1 yr Both W
72 No Yes Yes 3 Yes No No No No No No No Yes 2 yrs D D Yes 2 yrs D D
73 Yes No No 6 No No No No No No No No Yes 5 yrs Both D Yes 5 yrs Both D
74 No Yes No 0 Yes No No No No No No No Yes 5 yrs Both D No
75 No No No 0 No Yes No No No Yes No No Yes 6 months D D Yes 6 monnths D D
76 No No No 0 No No No No No No No No No No
77 No No No 2 No Yes No No No No No No Yes 1 yr D D Yes 1 yr D D
78 Yes Yes No 0 Yes No No No No No No No Yes 3 yrs D D No
79 Yes Yes Yes 3 No Yes No No No No No No Yes 6 months D D Yes 6 monnths Both D
80 Yes No No 2 No Yes No No No No No No Yes 6 months Both D Yes 6 monnths Both D
81 Yes Yes No 4 Yes No No No No No No No Yes 2 months D W No
82 No No No 3 No Yes No No No No No No Yes 6 months D D No
83 Yes Yes Yes 3 No Yes No No No No No No Yes 2 months Both W No
84 No No Yes 3 No Yes Yes No No No No No No No
85 No Yes No 3 No Yes No No No No No No No Yes 2 months Both D
86 No No No 8 Yes Yes No No No No No No Yes 1 month Both D Yes 1 month D D
87 No No Yes 1 Yes Yes No No No No No No Yes 5 yrs D D No
88 No Yes Yes 2 Yes No No No No No No No No No 5 months D D
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89 No Yes Yes 2 No No No No No No No No Yes 5 months Both D Yes 5 months D M
90 No Yes Yes 6 No Yes No No No No No No No Yes 3 months Both W
91 Yes Yes No 3 No Yes Yes No No No No No Yes 3 months D W Yes 3 months D W
92 No No No 2 No No No No No No No No No Yes 4 months D D
93 No No No 3 No No No No No No No No Yes 2 yrs D D Yes 2 yrs D D
94 Yes No No 1 Yes Yes No No No No No No Yes 1 yr D D Yes 1 yr D D
95 Yes Yes No 8 Yes Yes No No No No No No Yes 1 yr D D Yes 5 yrs Both D
96 Yes Yes Yes 2 Yes Yes No No No No No No Yes 1 month N W No
97 No Yes No 2 No Yes No No No No No No Yes 8 months D D Yes 8 months D D
98 Yes No No 2 No Yes No No No No No No Yes 6 months D D Yes 6 monnths D D
99 No No No 2 No No No No No No No No Yes 1 month Both D Yes 1 month Both D
100 Yes Yes No 2 Yes No No No No No No No Yes 2 yrs D W Yes 2 yrs D W
101 No Yes Yes 6 No Yes No No No No No No Yes 2 weeks Both D Yes 2 week D D
102 No Yes No 4 No Yes No No No No No No Yes 8 yrs Both D Yes 8 yrs Both D
103 Yes No No 2 No No No No No No No No No Yes 1 yr D W
104 Yes Yes Yes 5 Yes No No No No No No No No Yes 10 days Both D
105 Yes No No 2 No No No No No No No No Yes 1.5 yrs Both W No
106 Yes Yes No 1 No Yes No No No No No No Yes 3 months Both D Yes 3 months D D
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1 Increase Increase No No No No No No No No No No No
2 Increase Increase No No No No Yes Yes Yes No No No No
3 Increase No Yes 6 yrs moderate No No Yes Yes Yes No Yes Yes No
4 Increase No No No No Yes No No No No No No
5 Increase Increase Yes int sol No Yes No Yes No Yes No Yes Yes No
6 Increase Yes int Both No No No No Yes Yes Yes Yes Yes No
7 Yes int sol No Yes No No No No No No No No
8 Increase No No No No No No No No Yes No No
9 Increase Increase No No No No Yes Yes Yes No No No No
10 Increase Yes cont sol No No No Yes No Yes No No No No
11 Increase Increase No No No No No Yes Yes No No No No
12 No No No No No No No No No No No
13 No No No No No Yes Yes No No No No
14 Increase Increase No Yes 10 days mild Increase No No No Yes Yes No Yes No No
15 Increase Increase No No Yes No No Yes Yes No Yes Yes No
16 Increase Increase Yes int sol No No No No Yes Yes No Yes Yes No
17 Increase Increase No No Yes No Yes Yes Yes No No No No
18 No No No No No Yes No No No Yes No
19 Yes int sol Yes 4 months moderate No No No No No No No No No
20 Increase Increase No No No No No Yes No No No No No
21 Increase No No No No Yes Yes Yes No Yes No No
22 Increase No Yes 1 month mild No No No No Yes Yes No No No
23 Increase Increase No Yes 3 yrs moderate No Yes Yes Yes Yes No Yes Yes No
24 Increase Increase Yes int sol Yes 8 yrs moderate No No Yes Yes Yes Yes Yes Yes Yes
25 Increase No Yes No Yes Yes Yes No Yes Yes Yes
26 Increase Increase Yes int sol No Yes No Yes Yes Yes Yes Yes No No
27 Increase No Yes 2 months moderate Increase Yes No Yes Yes Yes No No No No
28 Increase No No No No No Yes Yes No No No No
29 Increase No Yes 3 months moderate Increase No No No No No No No No No
30 Increase Increase No No No No Yes No No No Yes No No
31 Increase No Yes 6 months mild No No Yes No No No No No No
32 Yes int sol No No No No Yes No No No No No
33 No Yes 2 yrs mild Increase Yes No Yes Yes Yes No No No No
34 No No No No No Yes Yes No No No No
35 Increase Yes int liquids No Yes No No Yes No No Yes No No
36 Increase Increase No No No No No No No No Yes Yes No
37 Increase Increase Yes int sol No Yes No No No No No No No No
38 Increase No Yes 3 months mild Increase No No No Yes Yes No Yes Yes No
39 No No No No No No No No Yes Yes No
40 Increase Increase No No No No No No No No No No No
41 No Yes 2 yrs moderate Increase No No No Yes Yes No No No Yes
42 Increase No No No No No Yes Yes No No No No
43 No No Yes No Yes Yes No No No No No
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44 Increase Increase Yes int sol No No No Yes Yes Yes No No No No
45 Increase Increase Yes int sol Yes 1 yr mild Yes No No No Yes No No No No
46 Increase Increase No No No No Yes Yes Yes No No No No
47 Yes int sol Yes 2 yrs moderate Increase No No No Yes No No No No No
48 Increase No Yes 1 yr mild Yes No Yes No Yes No No No No
49 No No No No Yes No No No No No No
50 Increase Increase No No No No Yes Yes Yes No Yes Yes No
51 Increase Increase No Yes 2 weeks mild Yes No Yes Yes Yes Yes Yes Yes No
52 Increase Increase No No No No No Yes Yes No Yes Yes No
53 Increase No No Yes No No No No No No No No
54 Increase Increase Yes cont sol Yes 3 months moderate Increase No Yes Yes Yes Yes No Yes No No
55 Increase Increase Yes int liquids No Yes Yes No Yes Yes No No No No
56 Increase No No No No No No No No No No No
57 Increase Increase Yes int sol Yes 3 yrs moderate Yes No Yes No No Yes No No No
58 Increase Increase No No No No No No Yes No No No No
59 Increase Increase Yes int Both No No No Yes Yes Yes No No No Yes
60 Increase Yes int sol Yes 2 yrs moderate No No No Yes Yes No Yes Yes No
61 Increase Yes int sol No Yes No No Yes Yes No No Yes No
62 Increase No No No No Yes Yes Yes No Yes Yes No
63 Increase Increase No Yes 1 yr moderate No No Yes Yes Yes No No No No
64 No No No No Yes No No No Yes Yes No
65 Increase Increase Yes int sol Yes 1.5 yrs moderate Yes No No Yes Yes Yes Yes Yes Yes
66 Increase No No No No No No No No No No No
67 Increase Yes int sol No Yes No Yes Yes Yes No Yes No No
68 Increase Increase Yes int sol Yes 2 months moderate Increase No No Yes Yes Yes No Yes No Yes
69 Increase Increase Yes cont Both No No No Yes Yes Yes No No No No
70 No No No No No No No Yes No No No
71 Increase Yes int Both No No Yes Yes Yes No No No No No
72 Increase No No No No No Yes Yes No Yes No No
73 Increase No No Yes No No No No No No No No
74 No No No No No Yes Yes No Yes Yes No
75 Increase Increase Yes int sol Yes 6 months moderate Yes No No No No No Yes No No
76 No Yes 1 month severe Increase Yes No Yes Yes Yes Yes Yes No No
77 Increase Increase Yes int sol Yes 1 yr moderate Increase No No Yes No No Yes No No No
78 No No Yes No No Yes Yes No No No No
79 Increase Increase Yes int sol No Yes No Yes Yes Yes Yes No No No
80 Increase Increase Yes int sol No Yes No Yes Yes Yes Yes No Yes Yes
81 No Yes 1 week mild No No Yes Yes Yes Yes No No No
82 Yes int sol Yes 5 yrs mild Increase Yes No No No No Yes No No No
83 No Yes 3 yrs moderate No No Yes No No No Yes No No
84 No Yes 5 yrs mild Increase No No Yes No No No No No No
85 Increase Increase No Yes 2 months severe Increase No No Yes No No No No No No
86 Increase Increase No Yes 1 month mild Increase Yes No No Yes Yes No No No No
87 No No No No No No No No No No No
88 Increase Increase Yes int sol No No No No Yes Yes Yes No Yes No
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89 Increase Increase No No Yes No Yes No No Yes No No No
90 Increase No Yes 3 months mild Increase No No Yes Yes Yes No No No No
91 Increase Increase No No No No No No No No No No No
92 Increase No No No No No No No No No No No
93 Increase Increase No No No No No No No No No No No
94 Increase Increase Yes int sol No No No No Yes Yes No Yes No No
95 Increase Increase No No No No Yes Yes Yes Yes Yes Yes No
96 Yes int Both No No Yes No No No Yes No No No
97 Increase Increase No No No No Yes Yes Yes No Yes No No
98 Increase Increase No No No No No Yes Yes No No No Yes
99 Increase Increase No Yes 1 month mild Increase No No No No No No No No No
100 Yes cont sol No No Yes Yes Yes Yes No No No Yes
101 Increase Increase Yes int sol No No No No Yes Yes No No No No
102 Increase Yes int sol Yes 2 months mild No No No No No No No Yes No
103 Increase Yes int sol No Yes No Yes Yes Yes Yes No No No
104 Increase Yes int sol No No No Yes No No No No No No
105 No No No No No Yes Yes No No No No
106 Increase No No No No Yes Yes Yes No No No No
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1 No No No No Yes No 1219/02 U Yes No Yes Yes
2 No No No Yes No No 825/03 N Yes No Yes Yes
3 No No No No No No 252/03 N Yes No Yes Yes
4 No No No Yes No No 1955/07 I U Yes Yes Yes Yes
5 Yes Yes Yes Yes Yes No DM 3385/04 U No Yes No Yes Yes
6 No No No Yes Yes No 1376/03 N N I No Yes No Yes Yes
7 No No No No Yes No 2816/04 N I U No Yes No Yes Yes
8 No No No nn No No 2431/03 lax LES Yes No Yes Yes
9 No No No Yes No No Htn,DM 406/03 lax LES I Yes Yes Yes Yes Yes
10 No No No Yes No No 4048/04 U No No No Yes Yes
11 No No No No No No Htn 352/04 Yes Yes No Yes Yes
12 No No No Yes No No 3543/04 U No Yes Yes Yes Yes
13 No No No Yes No No trauma 2759/06 Yes Yes Yes Yes
14 No No No Yes No No 4128/04 E E Yes No Yes Yes
15 No No No No Yes Yes 4880/004 N Yes No Yes Yes
16 No No No Yes No No 2029/05 N Yes No Yes Yes
17 Yes No No No No No Hypothyr 23/2006 E Yes No Yes Yes
18 No No No No No No 633/05 I I Yes Yes No Yes Yes
19 No No No No No No DM 1475/05 N No No Yes Yes
20 Yes Yes Yes No No No Hypothyr 2005 I Yes Yes No Yes Yes
21 No No No Yes Yes No Infertility 1674/05 I Yes No Yes Yes
22 Yes Yes Yes No No No DM/Htn 2102/05 N Yes No Yes Yes
23 No No No Yes No No 2223/05 E E Yes No Yes Yes
24 No No No No No No 2698/05 U Yes Yes No Yes Yes
25 No Yes No No Yes No 3141/06 N Yes No Yes Yes
26 No No No Yes Yes No Hypoth,IH 621/06 N No Yes No Yes Yes
27 No No Yes No No No 2041/06 lax LES I Yes Yes No Yes Yes
28 No No No No No No Htn 49/08 lax LES Yes No Yes Yes
29 No No No Yes Yes No 962/06 N Yes No Yes Yes
30 Yes Yes Yes Yes No No 533/08 I,E Yes Yes Yes Yes
31 Yes No No Yes No No 231/08 N Yes No Yes Yes
32 No No No Yes Yes No 1379/06 N Yes No Yes Yes
33 No No No No No No DM/Htn 537/08 I Yes No Yes Yes
34 No No No Yes Yes Yes 1777/06 lax LES U Yes No Yes Yes
35 No Yes Yes n Yes No 2308/06 N Yes No Yes Yes
36 No No No Yes No No 1839/06 N Yes No Yes Yes
37 No No No Yes Yes No 2597/06 lax LES Yes No Yes Yes
38 Yes Yes No Yes No No 2576/06 E,U Yes No Yes Yes
39 No No No Yes Yes No DM 2660/06 N No No Yes Yes
40 No No No No No No 2604/06 U U Yes No Yes Yes
41 Yes Yes Yes Yes No No N Yes No Yes Yes
42 No No No Yes Yes No 3000/06 N Yes No Yes Yes
43 No No No No No No 967/07 U Yes No Yes Yes
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44 Yes No No Yes No No 3927/06 I Yes No Yes Yes
45 No No No Yes Yes No 3332/06 lax LES Yes No Yes Yes
46 No No No Yes No No 160/07 E Yes Yes Yes Yes
47 No No No Yes No No Htn 221/07 bile gastr I Yes Yes Yes Yes
48 No No No No No No 150/07 N U No No Yes Yes
49 No No No No No No 589/07 N Yes No Yes Yes
50 No No No Yes No No N Yes No Yes Yes
51 No No No Yes No No DM 2390/07 N Yes No Yes Yes
52 No No No No No No 944/07 I I,U Yes No Yes Yes
53 No No No Yes No No 874/07 lax LES Yes No Yes Yes
54 Yes Yes Yes Yes Yes No 916/07 I Yes No Yes Yes
55 Yes Yes No Yes No Yes 324/07 I I Yes No Yes Yes
56 No No No No Yes No 948/07 N Yes No Yes Yes
57 Yes Yes No Yes No No Htn 1675/07 I Yes No Yes Yes
58 No No No Yes Yes No 1384/07 lax LES Yes No Yes Yes
59 No Yes No Yes Yes No 2538/07 N Yes No Yes Yes
60 Yes No No Yes Yes Yes 1720/07 N Yes No Yes Yes
61 No Yes Yes Yes Yes No Htn 1556/07 lax LES Yes Yes No Yes Yes
62 No No No No No No 1508/07 pale Yes No Yes Yes
63 No Yes Yes Yes No No 1671/07 I Yes No Yes Yes
64 No No No No No No 1669/07 N I Yes No Yes Yes
65 Yes Yes Yes Yes Yes Yes 828/06 OGJ polyp N I Yes Yes No Yes Yes
66 Yes No No Yes No No Htn Yes Yes No Yes Yes
67 No No Yes Yes No No 1950/07 I Yes No Yes Yes
68 Yes Yes Yes Yes No No 2726/07 Yes Yes No Yes Yes
69 No No No Yes Yes No Htn 1861/07 N Yes No Yes Yes
70 No No No No No No DM 57/08 U Yes Yes No Yes Yes
71 No No No No No No 2364/07 N
72 No No No No No No 6077/07 I Yes No Yes Yes
73 No No No Yes Yes No 2518/07 U Yes No Yes Yes
74 No No No No No No 349/04 U Yes No Yes Yes
75 No No No Yes No No DM,Htn Yes No Yes Yes
76 No No No No Yes No 2086/07 N Yes No Yes Yes
77 No No No Yes No No 2161/07 E Yes No Yes Yes
78 No No No No No Yes 12/3/2007 I Yes No Yes Yes
79 No Yes No Yes No No Htn 3222/07 N Yes Yes Yes Yes
80 Yes Yes Yes No Yes No 3341/07 lax LES I Yes No Yes Yes
81 No Yes Yes Yes No No 198/08 I Yes No Yes Yes
82 Yes Yes Yes Yes No No 157/08 I No No Yes Yes
83 No No No Yes Yes Yes DM 421/08 N Yes Yes Yes Yes
84 Yes Yes Yes Yes No No 582/08 N Yes No Yes Yes
85 No No No Yes No No Htn 317/08 N Yes No Yes Yes
86 No No No Yes No Yes 556/08 N Yes No Yes Yes
87 Yes No No Yes No No 927/08 N Yes No Yes Yes
88 No Yes Yes No Yes No 653/08 N Yes No Yes Yes
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89 Yes No No No Yes No 810/08 N Yes No Yes Yes
90 No No No No No No 896/08 N Yes No Yes Yes
91 No Yes No Yes No No 978/08 N Yes No Yes Yes
92 No No No No No No 757/08 diverticul Yes No Yes Yes
93 No No No No Yes No 1816/08 N Yes No Yes Yes
94 No No No Yes No No 1277/08 I Yes No Yes Yes
95 Yes No No No No Yes Yes Yes Yes Yes
96 Yes No No No No No Yes No Yes Yes
97 No No No Yes Yes No 1429/08 N Yes No Yes Yes
98 Yes No No No Yes No 517/08 I Yes No Yes Yes
99 No No No Yes No No DM
100 No No No Yes No No DM 1599/08 I,U,strictur Yes Yes Yes Yes Yes
101 No No No No No No 1791/08 I Yes Yes Yes Yes
102 No No No No Yes No 44953 U Yes No Yes Yes
103 No No No No No No 108/08 I U perf U Yes No Yes Yes
104 No No No No Yes No HIV? 1732/08 I-monilial Yes No Yes Yes
105 No No No Yes Yes No I I Yes Yes No Yes Yes
106 No No No Yes Yes No I Yes No Yes Yes
